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Accumulating evidence implicates cholesterol metabolism in the pathogenesis of 
Alzheimer’s disease (AD). However, the underlying mechanisms are not well 
understood. In the brain, cholesterol is synthesized locally by different cell types 
during development and in adulthood. The current understanding is that astrocytes 
are likely the major producers of cholesterol in the adult brain. However, in vivo 
evidence has been limited by the lack of genetic tools that allow efficient targeting 
of gene function in adult astrocytes. In this study, a newly generated BAC transgenic 
mouse line that expresses tamoxifen inducible Cre recombinase under control of 
the Aldh1l1 promoter was characterized. Analyses revealed that astrocytes in brain 
and spinal cord are targeted with high efficiency. Using this mouse line we 
inactivated cholesterol synthesis in adult astrocytes by targeting of squalene 
synthase (SQS), the enzyme catalyzing the first committed step in cholesterol 
biosynthesis. Conditional mutants did not show signs of brain pathology and mutant 
astrocytes were viable. Interestingly, albeit successful inactivation of SQS in 
astrocytes, brain cholesterol homeostasis was largely unaltered, suggesting 
compensatory efforts by other cell types. To address the role of astrocytic 
cholesterol synthesis in cerebral β-amyloidosis, we crossed conditional mutants with 
5xFAD mice, an animal model of AD. In the hippocampus of these compound 
mutants, we found reduced deposition of Aβ42 peptides accompanied by increased 
expression of Trem2 (triggering receptor expressed on myeloid cells 2). Although 
further investigation is required, Trem2 could potentially facilitate Aβ clearance by 
microglia cells in these mutants. Together, this study indicates that astrocytic 
cholesterol synthesis is not required in adult mice and underlines the importance of 





1.1 Peripheral cholesterol metabolism 
 
Cholesterol is an essential component of all animal cell membranes constituting 20-
25% of plasma membrane lipids in most cells (Dietschy and Turley, 2004). 
Furthermore, cholesterol is the sole precursor of steroid hormones (Rone et al., 
2009) and 7-dehydrocholesterol is involved in vitamin D production (reviewed in 
(Holick, 2007). Cholesterol is obtained from the diet and synthesized de novo in 
various organs. After uptake of cholesterol in the small intestine and esterification in 
enterocytes, triglycerides and esterified cholesterol are transported together in 
lipoprotein particles called chylomicrons within the lymph. Triglycerides are then 
hydrolyzed by the enzyme LPL (lipoprotein lipase) supplying peripheral tissues with 
free fatty acids and monoacylglycerol generating chylomicron remnants that enter 
the blood circulation. Chylomicron remnants are then taken up by the liver via the 
interaction of apolipoproteins on the chylomicron remnant surface and LDL (low 
density lipoprotein receptor) and LRP (low density lipoprotein receptor-related 
protein) receptors on hepatic endothelial cells (reviewed in Cooper, 1997). The liver 
is the central organ involved in adjusting the serum cholesterol level and the supply 
of lipids to peripheral organs via the blood circulation. Cholesterol is also secreted 
from the liver via bile. In the blood, lipids including cholesterol are transported via 
VLDL (very low density lipoprotein) and LDL (low density lipoprotein) particles to 
peripheral organs or back to the liver via HDL (high density lipoprotein) particles. 
Uptake of cholesterol from lipoprotein particles by the target organ is mediated by a 
specific set of apolipoproteins located on the surface of each lipoprotein particle and 
their interaction with receptors of the LDLR family and scavenger receptors SRB1 
(scavenger receptor class B member 1) and CD36 (reviewed in Li et al., 2001; Zani 
et al., 2015). The composition of apolipoproteins is specific to each type of 
lipoprotein particle while single apolipoproteins can be present either on some 
lipoprotein particles or on several. Apolipoprotein B48 (ApoB48) for example is 
located mainly on chylomicrons and chylomicron remnants while apolipoprotein E 
(ApoE) is present on chylomicrons, chylomicron remnants, VLDL and HDL particles 




1.2 Cholesterol metabolism in the brain 
 
In the healthy brain, the blood-brain barrier (BBB) prevents entry of peripheral 
cholesterol from the circulation and brain resident cells synthesize cholesterol locally 
(Björkhem and Meaney, 2004). However, upon BBB impairment in pericyte deficient 
mice increased cholesterol influx in the brain was measured accompanied by 
dysregulation of cholesterol synthesis and excretion (Saeed et al., 2014). 
Furthermore, disturbance of BBB integrity during a variety of neurodegenerative 
diseases could allow access of peripheral cholesterol to the central nervous system 
(CNS) as demonstrated in mouse models of Pelizaeus-Merzbacher disease and 
multiple sclerosis (Saher et al., 2012; Berghoff et al., 2017b). 
 
All cell types of the brain are capable of cell autonomous cholesterol biosynthesis 
(Figure 1). Cholesterol synthesis is a complex process that is divided into two parts 
(reviewed in Saher et al., 2011). In the first part, the isoprenoid biosynthesis pathway 
(also called mevalonate pathway), acetyl-CoA is converted to farnesyl-
pyrophosphate by a series of enzymatic reactions including the rate-limiting 
Figure 1: Cholesterol metabolism in the brain. All cells of the brain are able to synthesize 
cholesterol themselves. Detailed description in the text. BBB, blood-brain barrier, Chol, 
cholesterol, 24-OHC, 24(S)-hydroxycholesterol, ApoE, apolipoprotein E, ABCA1, ATP-
binding cassette subfamily A member 1, CYP46, cholesterol 24-hydroxylase, LDL-R, low-
density lipoprotein receptor, HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase, SREBP, 




conversion of HMG-CoA to mevalonate by HMGCR (3-hydroxy-3-methyl-glutaryl-
CoA reductase). In the second part, the sterol biosynthesis pathway, squalene 
synthase (SQS, encoded by the Fdft1 gene) catalyzes the first committed step in 
cholesterol synthesis by conversion of farnesyl-pyrophosphate to squalene. 
Cholesterol is finally generated via two different pathways from lanosterol with the 
conversion of desmosterol to cholesterol by DHCR24 (24-dehydrocholesterol 
reductase) being the final step in the so-called Bloch pathway and the conversion 
of 7-dehydrocholesterol to cholesterol by DHCR7 (7-dehydrocholesterol reductase) 
in the so-called Kandutsch-Russel pathway. Cellular cholesterol homeostasis is 
tightly regulated. Cholesterol concentration is measured in the endoplasmic 
reticulum (ER) by SCAP (SREBP cleavage-activating protein) complexed with 
SREBP (sterol regulatory element-binding protein) transcription factors (reviewed in 
Eberlé et al., 2004). When cellular cholesterol concentration is low SCAP-mediated 
SREBP translocation to the nucleus induces expression of genes involved in lipid 
synthesis including Hmgcr (Figure 1). While SREBP transcription factors exert 
partially overlapping functions in lipogenesis (reviewed in Eberlé et al., 2004), 
SREBP2 (encoded by the Srebf2 gene) seems to be more specific to cholesterol 
synthesis (Horton et al., 1998). In contrast, LXR (liver-X receptor) transcription 
factors are involved in the reduction of cellular cholesterol content. LXR-mediated 
transcriptional regulation is induced by cholesterol and oxysterols that are generated 
upon cellular cholesterol overload (reviewed in Kang and Rivest, 2012). Activation 
of LXR leads to transcriptional downregulation of Fdft1 (Wang et al., 2008) and 
induces expression of Apoe as well as of ATP-binding cassette transporters Abca1 
and Abcg1 (Kang and Rivest, 2012), which are critically involved in cellular 
cholesterol export via lipoprotein particles (reviewed in Pfrieger and Ungerer, 2011). 
Cholesterol transport between different cells of the brain is mediated via lipoprotein 
particles that under normal conditions are likely produced by astrocytes (reviewed 
in Pfrieger and Ungerer, 2011) and display similar densities to HDL particles (LaDu 
et al., 1998). Astrocyte derived lipoprotein particles contain ApoE and ApoJ 
(encoded by the Clu gene) apolipoproteins in vitro (Pasinetti et al., 1994; LaDu et 
al., 1998; Fagan et al., 1999; DeMattos et al., 2001). Uptake of cholesterol from 
lipoprotein particles is mediated by members of the LDLR family (Figure 1). 
Cholesterol is not degraded within the brain but excreted in the form of oxysterols 
that can readily pass the BBB. The most prominent oxysterol in the brain is 24(S)-
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hydroxycholesterol that is generated by the enzyme cholesterol 24-hydroxylase 
(encoded by the Cyp46a1 gene) predominantly expressed by neurons (Dietschy 
and Turley, 2004). However, excretion of glia derived cholesterol likely involves a 
different pathway (Xie et al., 2003) via ApoE lipoprotein particles (Figure 1). The 
enzymes cholesterol 25-hydroxylase (encoded by the Ch25h gene) and sterol 27-
hydroxylase (encoded by the Cyp27a1 gene) generating 25-hydroxycholesterol and 
27-hydroxycholesterol, respectively are less prominent in brain (reviewed in Russell, 
2000) while expression of Ch25h was found in acutely isolated microglia (Ceglia et 
al., 2015). 
 
1.2.1 Contribution of different cell types to brain cholesterol homeostasis 
 
How different cell types contribute to cholesterol homeostasis in the brain is difficult 
to assess since all cell types of the brain are capable of cell autonomous cholesterol 
synthesis and can also benefit from horizontal cholesterol transfer via HDL-like 
lipoprotein particles (see above). It is plausible that cellular cholesterol demand is 
high at times of membrane expansion and cell differentiation during development. 
The current understanding is that the cell type predominantly producing cholesterol 
switches from neurons during embryogenesis to oligodendrocytes during postnatal 
myelination and to astrocytes in the adult brain (Pfrieger and Ungerer, 2011; Saher 
and Stumpf, 2015). However, to which extent different cell types contribute to 
cholesterol homeostasis in the adult brain in vivo is incompletely understood. 
Turnover of bulk cholesterol in the adult rodent brain is low with an estimated half-
life of several months (Sérougne-Gautheron and Chevallier, 1973; Björkhem et al., 
1997; Dietschy and Turley, 2001). However, the vast majority (~70-80%) of brain 
cholesterol in adult animals resides in myelin with low turnover (Smith, 1968; Ando 
et al., 2003) and high cholesterol turnover was suggested for individual neurons and 
astrocytes  (Dietschy and Turley, 2001; Pfrieger and Ungerer, 2011). Thus, genetic 
tools are required to analyze cholesterol metabolism cell type specifically.  
The use of SQS-flox mice (Saher et al., 2005) allows genetic inactivation of 
squalene synthase by targeting the Fdft1 gene in different cell types using specific 
Cre driver lines. Ablation of SQS function in all neurons and glial cells was lethal in 
newborn mice (Saito et al., 2009) highlighting the importance of cholesterol 
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synthesis in the CNS. Inactivation of SQS in myelinating glia resulted in severe 
dysmyelination leading to ataxia and tremor in mutant mice (Saher et al., 2005). 
Increased levels of ApoE and LRP indicated compensatory cholesterol transfer by 
surrounding wild type cells mediating oligodendrocyte survival and generation of 
myelin (Saher et al., 2005). These findings underscore the importance of 
endogenous cholesterol synthesis in oligodendrocytes during myelination.  
  
1.2.1.1 Neuronal cholesterol synthesis 
 
Cholesterol secreted in ApoE-containing lipoprotein particles by astrocytes has 
been shown to promote synaptogenesis in cultured neurons (Mauch et al., 2001). 
Together with evidence largely based on in vitro studies this finding has promoted 
the notion that neurons rather rely on astrocyte derived cholesterol than synthesize 
cholesterol themselves (Pfrieger, 2003). This hypothesis was supported by the 
finding that cultured neurons produced cholesterol less efficiently than astrocytes 
(Nieweg et al., 2009). Do neurons require cell autonomous cholesterol synthesis in 
vivo? In adult mice SQS was not required for survival and function of cerebellar 
granule cells (Fünfschilling et al., 2007). Similarly, upon postnatal inactivation of 
SQS in forebrain projection neurons mutant mice were healthy and lacked any signs 
of brain pathology (Fünfschilling et al., 2012). Increased levels of SQS protein in 
astrocytes as well as upregulation of ApoE indicated that survival and functional 
preservation of mutant neurons was supported by astrocyte derived cholesterol 
(Fünfschilling et al., 2012). However, ablation of SQS in projection neurons during 
development resulted in layer-specific neuronal death and reduction of cortical 
projections despite evident microglial support including upregulation of ApoE 
expression (Fünfschilling et al., 2012). These findings show that neurons require cell 
autonomous cholesterol synthesis during development but can rely on glial 






1.2.1.2 Role of astrocytes in cholesterol metabolism 
 
Astrocytes are generated from neural precursor cells postnatally after neurogenesis 
is largely complete (Vallejo, 2009). Throughout development and also in the adult 
brain astrocytes are critically involved in establishment and maintenance of brain 
function. Roles of astrocytes have been identified in neuronal maturation and 
synaptogenesis, establishment and maintenance of the BBB, ion buffering and 
recycling of neurotransmitters as well as neuroinflammation and responses to injury 
(reviewed in Wang and Bordey, 2008). Furthermore, astrocytes support neurons 
with cholesterol in vitro and in vivo (see above). The extent of astrocyte involvement 
in brain cholesterol metabolism in vivo however is largely unknown. Genetic 
inactivation of the sterol sensor SCAP in GFAP (glial fibrillary acidic protein) 
expressing astrocytes resulted in severe brain defects including microcephaly and 
reduction of cholesterol and fatty acid synthesis leading to premature death 
(Camargo et al., 2012). These mice also exhibited defects in the maturation of 
presynaptic terminals resulting in reduced short- and long-term synaptic plasticity 
(van Deijk et al., 2017). These studies show that astrocyte derived lipids including 
cholesterol are crucial in brain development. Genetic deletion of SCAP however 
likely affects transcription of a variety of genes regulated by SREBP (Matsuda et al., 
2001; Rome et al., 2008) and therefore a different approach is required focusing on 
cholesterol synthesis. 
Understanding of the role of astrocytic cholesterol synthesis in the adult brain is 
limited by the lack of genetic tools that allow specific and efficient targeting of these 
cells. In order to study astrocyte function at desired time points several transgenic 
lines have been developed that express tamoxifen inducible Cre recombinase under 
control of promoters active in astrocytes (Ganat et al., 2006; Hirrlinger et al., 2006; 
Mori et al., 2006; Chow et al., 2008). Although these mouse lines are useful tools to 
target astrocytes in many brain regions (e.g. corpus callosum or cerebellum) only 
subsets of astrocytes are targeted in other regions, especially the cortex and spinal 
cord. The Aldh1l1 (aldehyde dehydrogenase 1 family member L1) gene is 
expressed in a subset of radial glia during embryonic development (Anthony and 
Heintz, 2007) and neuronal precursors (Foo and Dougherty, 2013) and has been 
identified as a pan astrocyte marker in postnatal brain (Cahoy et al., 2008). Aldh1l1 
promoter driven expression of a fluorescent protein or Cre recombinase in BAC 
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transgenic mouse lines (Heintz, 2004; Yang et al., 2011) confirmed that Aldh1l1 is 
a specific marker for CNS astrocytes including cortical astrocytes. Recently, two 
BAC transgenic mouse lines expressing tamoxifen inducible Cre recombinase 
(CreERT2) under control of the Aldh1l1 promoter were generated. Characterization 
of transgene activity in one line revealed that >90% of astrocytes in the 
hippocampus, striatum and cortex were targeted after tamoxifen induction in adult 
mice (Srinivasan et al., 2016). Characterization of the other mouse line 





Figure 2: APP processing in the α- and β-secretase pathways. In the α-secretase 
pathway APP is first cleaved by α-secretase generating α-CTF (or C83) and sAPPα 
fragments followed by γ-secretase mediated shedding of p3 and AICD fragments. In the 
amyloidogenic β-secretase pathway, APP is cleaved by β-secretase generating β-CTF (or 
C99) and sAPPβ fragments. Processing by γ-secretase then generates AICD fragments and 
Aβ peptides that form oligomers and aggregate in extracellular deposits. APP, amyloid 
precursor protein, Aβ, amyloid-β, sAPP, soluble APP fragment, CTF, C-terminal fragment, 
AICD, APP intracellular C-terminal domain. Adapted from Maulik et al., 2013. 
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1.3 Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disease 
worldwide and the leading cause of dementia (Reitz et al., 2011). AD patients suffer 
from progressive memory loss, cognitive decline and eventually loss of vital 
neuronal function (reviewed in Alves et al., 2012; Tarawneh and Holtzman, 2012). 
Histopathological hallmarks of AD are extracellular deposits of amyloid-β (Aβ) 
peptides and the manifestation of intracellular neurofibrillary tangles consisting of 
hyperphosphorylated tau protein. The generation and deposition of misfolded Aβ 
peptides in the brain is termed cerebral β-amyloidosis. Aβ peptides are generated 
by sequential proteolytic processing of the amyloid precursor protein (APP) by β-
secretase (BACE1) and the γ-secretase complex, whereas initial processing by α-
secretase does not lead to Aβ generation (Figure 2). APP processing by γ-secretase 
generates Aβ peptides of varying length, of which Aβ40 is the most prominent in AD 
brains and Aβ42 likely the most toxic (reviewed in Karran et al., 2011).  Pathological 
changes also include activation of astrocytes and microglia around Aβ deposits and 
progressive loss of synapses as well as neuronal degeneration (reviewed in 
Duyckaerts et al., 2009). The cause of AD is unknown for the vast majority of cases 
(sporadic AD, SAD) but in approximately 1-5% of affected patients, disease 
development is linked to inherited genetic mutations (familial AD, FAD). These 
mutations have been identified in the gene encoding APP (Goate et al., 1991) or in 
the genes encoding PSEN1 (presenilin-1, Sherrington et al., 1995) and PSEN2 
(presenilin-2, Levy-Lahad et al., 1995; Rogaev et al., 1995), proteins that form the 
catalytic site of γ-secretase. These and several other mutations identified over the 
years have been shown to enhance the production of all Aβ peptides or increase 
the Aβ42/Aβ40 ratio in favor of the more readily aggregating Aβ42 peptide (Karran 
et al., 2011). These findings gave rise to the amyloid cascade hypothesis (Hardy 
and Selkoe, 2002) which suggests the generation and deposition of Aβ peptides as 
the driving force of AD disease progression. Disease onset in FAD is 20 to 30 years 
earlier than in the majority of SAD cases (Karran et al., 2011) with early biomarker 





Despite the differences in etiology, onset and disease progression between FAD 
and SAD, neuropathological changes are similar including Aβ deposition and tau 
aggregation. Finding the cause of SAD remains an important topic of current 
research and includes a great variety of different approaches (De Strooper and 
Karran, 2016).  
 
1.3.1 Role of cholesterol in Alzheimer’s disease 
 
The role of cholesterol in the pathogenesis of AD is an important topic of current 
research and still far from understood. The importance of cholesterol in AD is 
highlighted by the fact that 3 of the top 5 genetic risk factors for AD are involved in 
cholesterol metabolism (AlzGene database, Bertram et al., 2007). Furthermore, age 
as the highest risk factor for SAD also strongly affects lipid and cholesterol 
metabolism (Cutler et al., 2004). In AD patients clinical studies were conducted that 
aimed at reducing cholesterol levels by the use of statins. Results were controversial 
with some studies reporting beneficial effects while others did not (reviewed in 
Shepardson et al., 2011). Pleiotropic effects of statins likely contribute to the lack of 
a clear conclusion in these studies. Statins are HMGCR inhibitors and thereby not 
only inhibit cholesterol synthesis but affect isoprenoid synthesis in all cells. 
Isoprenoids are involved in post translational modification of small GTPases that 
regulate a variety of intracellular signaling cascades (reviewed in Wang et al., 2007). 
Similarly, treatment with the LXR/RXR agonist bexarotene, that modulates lipid 
metabolism initially showed promise in reducing Aβ deposition in some (Cramer et 
al., 2012), but not in other mouse models of AD (Veeraraghavalu et al., 2013) and 
failed to reduce plaque burden in AD patients (Cummings et al., 2016). Therefore, 
different approaches are required to modulate cholesterol levels in the brain more 
directly. 
Cholesterol metabolism in the brain is complex and incompletely understood (see 
above) which complicates research addressing the role of cholesterol in AD. Several 
lines of evidence derived from in vitro and preclinical studies suggest that 
cholesterol affects AD pathogenesis on cellular and organ level (reviewed in Maulik 
et al., 2013). Cholesterol enhances Aβ generation in cultured neurons (Simons et 
al., 1998; Wahrle et al., 2002) and promotes association and endocytosis of APP 
19 
 
and BACE1 in vitro (Schneider et al., 2008; Marquer et al., 2011). In early 
endosomes, APP is then cleaved by BACE1 generating the APP C-terminal 
fragment C99 (or β-CTF) which associates directly with cholesterol facilitating its 
localization to lipid rafts (Barrett et al., 2012). After recycling of APP/C99 from 
endosomes to the trans-Golgi network, γ-secretase processing of C99 generates 
Aβ peptides (Wahrle et al., 2002; Choy et al., 2012). Aβ peptides also directly bind 
cholesterol which promotes the generation of neurotoxic Aβ oligomers at the plasma 
membrane (reviewed in Di Scala et al., 2014).  
In addition to the role of cholesterol in Aβ generation, cumulating evidence also 
implicates cholesterol transport via ApoE lipoprotein particles in the deposition of 
Aβ. Research in this field has been promoted by the finding that homozygosity of 
the ApoE4 isoform significantly increases AD susceptibility making ApoE4 the top 
genetic risk factor for AD today (AlzGene database, Bertram et al., 2007). In animal 
models of AD, deletion of the Apoe gene resulted in strongly delayed deposition of 
Aβ without altering APP protein levels (Bales et al., 1997; Holtzman et al., 2000). 
Plaque formation was further delayed by additional introduction of the human Apoe 
gene in an isoform dependent manner with ApoE4 showing the least beneficial 
effect (reviewed in Tai et al., 2011). How ApoE influences Aβ deposition is 
incompletely understood. In vitro studies have shown that ApoE binds Aβ and 
affects its oligomerization and fibrillation (reviewed in Holtzman et al., 2012). In vivo, 
ApoE is primarily produced by astrocytes (reviewed in Vance and Hayashi, 2010) 
followed by import of lipids including cholesterol into ApoE lipoprotein particles 
(lipidation) via ABCA1 transporters (see above). Deletion of the Abca1 gene in AD 
mice decreased ApoE lipidation (Hirsch-Reinshagen et al., 2004) and increased Aβ 
deposition (Koldamova et al., 2005; Wahrle et al., 2005) while overexpression of 
Abca1 had the opposite effect (Wahrle et al., 2008). Genetic inactivation of the 
lipoprotein receptor LDLR resulted in increased ApoE levels in the brain (Cao et al., 
2005; Fryer et al., 2005) and had either no effect on Aβ deposition (Fryer et al., 
2005) or increased Aβ load in AD mouse models (Cao et al., 2005). Together these 
studies show that lipidation status and extent of ApoE-mediated lipid transport within 
the brain affect Aβ deposition. However, the underlying mechanisms are not well 
understood. Next to directly affecting distribution and subsequent deposition of Aβ, 
transport of Aβ associated with ApoE lipoprotein particles could also affect the 
clearance of these peptides by different cell types or their excretion from the brain 
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(Holtzman et al., 2012). Proteolytic degradation of Aβ is complex and can involve a 
variety of enzymes that are present in neurons and glial cells as well as in the 
extracellular space (reviewed in Saido and Leissring, 2012). The endopeptidase 
neprilysin (encoded by the Mme gene) is expressed in neurons and involved in Aβ 
degradation in axons and synapses (Fukami et al., 2002). Insulin-degrading enzyme 
(encoded by the Ide gene) is expressed by many cell types (Zhang et al., 2014) and 
is also located in the extracellular space (Saido and Leissring, 2012). In contrast, 
endothelin-converting enzymes ECE1 and ECE2 (encoded by Ece1 and Ece2) 
seem to degrade Aβ primarily intracellularly (Eckman et al., 2002). ApoE likely 
influences the degradation of Aβ by glial cells. Some studies proposed that ApoE 
and Aβ do not interact but rather compete for the receptor for endocytosis (Basak 
et al., 2012; Verghese et al., 2013), while another study proposed that lipidated 
ApoE lipoprotein particles associate with Aβ and mediate degradation either by 
pinocytosis or extracellular proteolytic cleavage (Jiang et al., 2008). Clearance of 
Aβ from the brain via the BBB might also be linked to cholesterol metabolism (Zhao 
et al., 2015). Excretion of cholesterol from the brain is mediated either via 24(s)-
hydroxycholesterol or ApoE (see above). Loss of Cyp46a1 did not affect Aβ 
deposition but increased life expectancy in an AD mouse model (Halford and 
Russell, 2009). Furthermore, Aβ binds to receptors of the LDLR family at the BBB 
(Zhao et al., 2015) which also mediate cholesterol transport within the brain (see 
above). Excretion of Aβ to the blood circulation is mediated by LRP1 (Storck et al., 
2016) and LRP2 (Bell et al., 2006). Overexpression of Ldlr decreased brain ApoE 
levels and increased efflux of Aβ at the BBB by an unknown mechanism (Castellano 
et al., 2012). In summary, several lines of evidence indicate a role of cholesterol in 
the generation, distribution and clearance of Aβ in the brain. However, the 
underlying mechanisms are not well understood and the contribution of different cell 







1.4 Aims of the study 
 
The contribution of astrocytes to brain cholesterol metabolism in vivo is not well 
understood due to the lack of genetic tools that allow efficient and specific targeting 
of adult astrocytes. Therefore, the first aim of this study was to characterize the 
newly generated Aldh1l1-CreERT2 mouse line (Winchenbach et al., 2016) 
regarding efficiency and specificity of Cre recombination in adult astrocytes. A direct 
approach to inactivate cholesterol synthesis in adult astrocytes has so far been 
lacking. To address this, in the second part of this project conditional mutant mice 
were generated that lack expression of SQS in astrocytes. Conditional mutants were 
analyzed with respect to astrocyte survival and viability. Astrocytes are tightly 
associated with microvessels in the brain (Mathiisen et al., 2010) and involved in 
regulation of BBB integrity via ApoE (Bell et al., 2012). Therefore, we assessed 
whether loss of cholesterol synthesis in astrocytes affects BBB integrity in 
conditional mutants. 
Evidence largely based on in vitro studies implicate cholesterol metabolism in the 
generation and deposition of Aβ in Alzheimer’s disease (Maulik et al., 2013). 
Astrocytes supply neurons with cholesterol via ApoE lipoprotein particles in vitro 
(Mauch et al., 2001). In vivo, SQS deficient neurons rely on cholesterol support by 
other cells, likely astrocytes, to maintain cellular cholesterol content and function 
(Fünfschilling et al., 2012). Reduction in neuronal cholesterol content inhibits the 
generation of Aβ in vitro (Simons et al., 1998; Wahrle et al., 2002) and direct 
interaction of APP and cholesterol could enhance β-secretase mediated Aβ 
production in cholesterol-rich lipid rafts (Barrett et al., 2012). Therefore, loss of 
cholesterol support by astrocytes could (I) influence neuronal cholesterol content 
and thereby the generation of Aβ. To address this, SQS was inactivated in 
astrocytes of 5xFAD mice, an animal model of AD (Oakley et al., 2006). In these 
compound mutants, APP processing and Aβ deposition was assessed. 
Lipid transport within the brain likely influences the distribution and deposition of Aβ 
(Holtzman et al., 2012). Decreased ApoE lipidation (Hirsch-Reinshagen et al., 2004) 
resulted in increased Aβ deposition in mice lacking Abca1 (Koldamova et al., 2005; 
Wahrle et al., 2005) while overexpression of Abca1 resulted in decreased Aβ 
deposition (Wahrle et al., 2008). Therefore, loss of cholesterol synthesis in 
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astrocytes could (II) modulate lipid transport via ApoE lipoprotein particles and 
thereby affect Aβ distribution and deposition. Furthermore, ApoE promotes the 
degradation of Aβ by astrocytes and microglia in vitro (Koistinaho et al., 2004; Jiang 
et al., 2008). Promoting lipidation of ApoE increased Aβ clearance by microglia in 
vitro and reduced Aβ deposition in vivo (Jiang et al., 2008). Thus, loss of SQS in 
astrocytes could (III) affect clearance and degradation of Aβ by astrocytes and 
microglia. To address these hypotheses (II, III), cholesterol homeostasis and 
astrocyte and microglia responses were analyzed.  
In a complimentary approach SQS was inactivated in forebrain projection neurons 
of 5xFAD mice to assess the role of neuronal cholesterol synthesis in cerebral β-
amyloidosis. As reported in vitro (Simons et al., 1998; Wahrle et al., 2002), loss of 
neuronal cholesterol synthesis could (IV) directly influence APP processing and Aβ 






















The majority of results (including the text) presented in section 2.1 and 2.2 are 
adapted from our manuscript published in 2016 (Winchenbach et al., 2016). 
2.1 Are astrocytes efficiently targeted in Aldh1l1-CreERT2 transgenic mice? 
 
Cre-mediated recombination of target genes in adult astrocytes requires the use of 
an inducible expression system, because many promoters of the astrocyte lineage 
are also active in multipotent neural stem cells in the subventricular and subgranular 
zones (Christie et al., 2013). Thus, transgenic mouse lines have been generated for 
tamoxifen-inducible Cre recombination of target genes in mature astrocytes (Ganat 
et al., 2006; Hirrlinger et al., 2006; Mori et al., 2006; Slezak et al., 2007; Chow et al., 
2008). However, none of them achieves sufficient recombination to study the 
function of genes in the majority of cortical and spinal cord astrocytes. Aldh1l1 has 
been identified as a highly specific marker for astrocytes in the brain (Cahoy et al., 
2008), which was verified in BAC transgenic mice with a fluorescent reporter protein 
or constitutive Cre expression under control of the Aldh1l1 promoter (Heintz, 2004; 
Yang et al., 2011). Therefore, our group has generated Aldh1l1-CreERT2 BAC 
transgenic mice expressing tamoxifen-inducible Cre recombinase under control of 
the Aldh1l1 promoter (Winchenbach et al., 2016) using the cloning strategy shown 
in Figure 3 A. In order to assess Cre recombination, mice carrying the Aldh1l1-
CreERT2 transgene (Figure 3 B) were crossed with ROSA26-tdTomato reporter 
mice (Madisen et al., 2010), termed astro-tdTo mice, or with ROSA26-Eyfp reporter 
mice (Srinivas et al., 2001). First, we determined the leakiness of reporter 
expression in adult Aldh1l1-CreERT2 mice. After corn oil injections in astro-tdTo 
mice, we found very few labeled cells (less than 5 per section), demonstrating that 
the inducible Cre system operates tightly. In parallel experiments, adult astro-tdTo 
mice were analyzed 7 days after tamoxifen induction. Sagittal brain sections 
revealed numerous tdTomato Cre reporter expressing cells, which in the forebrain 
exhibited the typical morphology of protoplasmic astrocytes (Figure 3). Co-labeling 
revealed that almost all S100beta (S100 calcium-binding protein B) positive cells in 








Analysis of astrocytes isolated from the cortex of adult astro-tdTo animals by 
fluorescence-activated cell sorting (FACS) revealed that 87.5 ± 1.8% (n = 3, ± 
s.e.m.) of cells labeled with the astrocyte marker ACSA2 (astrocyte cell surface 
antigen-2) expressed tdTomato while 77.0 ± 0.5% of tdTomato expressing cells 
were ACSA2 positive (Figure 3 E, F).  
 





  Cortex (astrocytes) tdTomato/S100beta 92 ± 2 1868 
EYFP/S100beta 62 ± 2 2038 
  Cerebellum (Bergman glia) EYFP/S100beta 89 ± 1 1460 
  Corpus callosum tdTomato/S100beta 85 ± 1 713 
  Fimbria tdTomato/S100beta 94 ± 2 145 
Specificity 
  Cortex (astrocytes) S100beta neg./tdTomato 12 ± 3 1943 
S100beta neg./EYFP 19 ± 3 1553 
  Cerebellum (Bergman glia) S100beta neg./EYFP 6 ± 1 1397 
  Fimbria S100beta neg./tdTomato 4 ± 1 143 
Figure 3: The Aldh1l1 BAC transgene efficiently targets CNS astrocytes. A) Scheme 
of the cloning strategy of the Aldh1l1-CreERT2 BAC transgene. B) Genotyping PCR from 
Aldh1l1-CreERT2 mice (+), wild type (wt) mice and from water (as a negative control). C) 
Direct fluorescence of the Cre-reporter tdTomato in sagittal brain sections of astro-tdTo 
mice. D) Immunolabeling of the astrocyte marker S100beta (green) in the cortex reveals 
almost complete overlap with the tdTomato Cre reporter (red) in astrocytes. Scale, 50 µm. 
E) Dot plot showing the gating strategy used during FACS analysis of cortical astrocytes of 
adult astro-tdTo mice immunolabeled with the astrocyte marker ACSA2. F) Quantification 
of cell populations shown in E. Values are expressed as per cent of all analyzed cells per 
animal (n = 3 animals, ± s.e.m.). Panels A, C and D adapted from Winchenbach et al., 2016. 
Initial generation of Aldh1l1-CreERT2 mice was performed by Dr. Gesine Saher. FACS 
analysis was performed together with Dr. Francesca Odoardi. 
Table 1: Efficiency and specificity of Aldh1l1-CreERT2 mediated recombination in 
brain. Efficiency and specificity of inducible Cre mediated recombination in adult Aldh1l1-
CreERT2 mice crossbred with Cre reporter ROSA26-tdTomato or ROSA26-Eyfp. For each 
value shown (average percentage), cells were counted on eight confocal images and two 
sections for each of n = 3-4 animals. Efficiency is expressed as percent Cre reporter positive 
cells of all S100beta labeled cells. Specificity is expressed as percentage of all Cre reporter 




For comparison, when using a less sensitive ROSA26-Eyfp Cre reporter line 
(Srinivas et al., 2001) in corresponding experiments, only two thirds of all S100beta 
positive cells in the cortex were also EYFP positive (Table 1). Thus, although both 
Cre reporter lines were generated as a knock-in into the endogenous ROSA26 
locus, the recombination efficacy achieved is clearly different, in agreement with 
previous reports (Srinivas et al., 2001; Madisen et al., 2010). This finding illustrates 
the need to determine recombination efficiency individually for each combination of 
Cre allele and floxed target gene. The expression pattern of some astroglial marker 
proteins, such as GFAP (glial fibrillary acidic protein), differs between protoplasmic 
astrocytes in the cortex and fibrous astrocytes in white matter. We therefore 
assessed the efficacy of Cre recombination separately for the corpus callosum, 
fimbria, hippocampus and spinal cord. Again, in all these regions a large majority of 
astrocytes, as defined by S100beta or GFAP, expressed Cre reporter, e.g. 85 ± 1% 
in the corpus callosum and 94 ± 2% in the fimbria (n = 3 animals, Figure 4, Table 
1). Co-labeling with GFAP was not used for cell counts because of the protein’s low 
abundance in cell bodies which makes unequivocal quantification difficult. In the 
cerebellum, a large fraction (89 ± 1%) of S100beta positive Bergman glia cells 
expressed the Cre reporter EYFP (Figure 4 C, Table 1). While 3.3 ± 0.3% of 
parvalbumin positive interneurons of the molecular layer expressed the tdTomato 
Cre reporter, none was double positive in corresponding experiments using the 
EYFP Cre reporter, confirming the sensitivity of the tdTomato reporter with a 






Figure 4: Inducible targeting of Bergman glia and white matter astrocytes. Co-
immunolabeling of the astrocyte marker S100beta or GFAP (green) with Cre reporter (in 
red: direct tdTomato fluorescence, GFP anti-YFP or RFP anti-tdTomato) in fimbria (A), the 
dentate gyrus of the hippocampus (B), cerebellum (C) and spinal cord (D) reveals almost 
complete overlap of the transgene with astrocytes. Scale, 50 µm. Adapted from 




Cre reporter expression was also observed in some neurons in the dentate gyrus 
and olfactory bulb, likely reflecting some recombination in adult neural stem cells in 
the subgranular and subventricular zone, followed by the migration of labeled 
progeny through the rostral migratory stream (Figure 3 C). Next, we compared 
Aldh1l1-CreERT2 mediated recombination with the expression pattern of EGFP in 
Aldh1l1-Egfp transgenic mice, generated with a similar BAC based strategy (Heintz, 
2004). As expected, reporter and EGFP expression was nearly identical in the 
cortex, confirming the high efficiency of CreERT2 mediated induction of the 
tdTomato reporter (Figure 5 A). Finally, in comparison with Slc1a3-CreERT2 (Mori 
et al., 2006), Aldh1l1-CreERT2 mediated recombination of the tdTomato reporter 
revealed nearly complete recombination of astrocytes in spinal cord white matter, 
whereas Slc1a3-CreERT2 mediated fluorescence appeared patchy (Figure 5 B).  
Figure 5: Comparison with other transgenes targeting astrocytes. A) Co-
immunolabeling of the Cre reporter tdTomato (red, anti-RFP) and EGFP (green, anti-GFP) 
in triple transgenic mice (Aldh1l1-CreERT2*ROSA26-tdTo*Aldh1l1-Egfp) in cortical 
sections. Scale, 50 µm. B) Direct fluorescene of the Cre reporter tdTomato (red) and DAPI 
(white) in spinal cord sections of astro-tdTo and Slc1a3-CreERT2*ROSA26-tdTo transgenic 




2.2 What is the cellular specificity of Cre expression in Aldh1l1-CreERT2 
mice? 
 
Next, the cell-type specificity of the Aldh1l1-CreERT2 transgene was tested. Co-
localization of tdTomato with markers for neurons (NSE, neuron specific enolase) 
or microglia (Iba1, ionized calcium binding adaptor molecule 1) was virtually absent 
(Figure 6, Table 2). However, we observed a small fraction of Cre reporter positive 
cells co-localizing with Olig2 (oligodendrocyte lineage transcription factor 2), a 
transcription factor found in all oligodendrocyte lineage cells, including 
oligodendrocyte precursor cells (Figure 6 B). 
Region Marker Co-labeled cells (%) Number of cells 
Cortex tdTomato/NSE 0 1000 
tdTomato/Iba1 0.4 ± 0.3 1157 
tdTomato/CAII 1.8 ± 0.9 443 
tdTomato/EYFP (NG2)* 3.4 ± 0.8 1275 
Cerebellum tdTomato/Parvalbumin 3.3 ± 0.3 2504 
* analyzed in triple transgenic mice (Aldh1l1-CreERT2*ROSA26-tdTomato*NG2-Eyfp) by 
Dr. Gesine Saher. 
Table 2: Specificity of Aldh1l1-CreERT2 mediated recombination in brain. Specificity 
of inducible Cre mediated recombination in adult astro-tdTo mice. For each value (average 
percentage), cells were counted on eight confocal pictures and two sections for each of n = 
4 animals. Specificity is expressed as percentage of cells that show Cre reporter expression 










Similarly, in triple transgenic mice that additionally express EYFP under control of 
the endogenous NG2 (neural/glial antigen 2) promoter (Karram et al., 2008), we 
identified 3.4% of double labeled cells, presumably oligodendrocyte precursor cells 
based on their localization and morphology. However, co-localization with a marker 
of mature oligodendrocytes (CAII, carbonic anhydrase 2) was negligible 12 days 
after tamoxifen injections, and did not increase in mice that were analyzed 27 weeks 
after recombination (tamoxifen induction at 16 weeks of age). This suggests that the 
small percentage of Aldh1l1-CreERT2 expressing NG2 glia does not give rise to 
oligodendrocytes. Taken together, Aldh1l1-CreERT2 mice efficiently and 
specifically target the majority of astrocytes in brain and spinal cord.  
 
2.3 Conditional inactivation of cholesterol synthesis in astrocytes 
 
Astrocytes are assumed to be the major cholesterol supplier in the adult brain 
(Dietschy and Turley, 2001) and enhanced production and transport of cholesterol 
by astrocytes supported neurons lacking cell autonomous cholesterol synthesis 
(Fünfschilling et al., 2012). However, an in vivo approach to directly assess the role 
of cholesterol synthesis specifically in adult astrocytes has been lacking. In order to 
address this question we crossed Aldh1l1-CreERT2 mice (Winchenbach et al., 
2016) harboring the Cre reporter tdTomato (Madisen et al., 2010) with SQS-flox 
mice (Saher et al., 2005). In SQS-flox mice exon 5 of the gene encoding squalene 
synthase (Fdft1), the enzyme catalyzing the first committed step in cholesterol 
biosynthesis, is flanked by loxP sites allowing inactivation of the gene upon Cre-
mediated excision of exon 5. Offspring of these animals with the genotype Aldh1l1-
CreERT2*ROSA26+/tdTomato*Fdft1flox/flox, referred to as astroSQS-tdTo mice, were 
injected with tamoxifen at 8 weeks of age to induce recombination in astrocytes 
Figure 6: Specificity of Aldh1l1-CreERT2 mediated recombination. A) Direct 
fluorescence of the Cre-reporter tdTomato (red) and immunolabeling of neurons (green, 
NSE) and microglia (green, Iba1) on cortical sections. Scales, 50 μm. B) Direct fluorescence 
of the Cre reporter tdTomato (red) and immunolabeling of mature oligodendrocytes (green, 
CAII, scale, 50 μm) and oligodendroglia (green, Olig2, scale, 20 μm). C) Co-immunolabeling 
of the Cre reporter tdTomato (red, anti-RFP) and EYFP (green, anti-GFP) in triple transgenic 
mice (Aldh1l1-CreERT2*ROSA26-Tdto*NG2-Eyfp) revealing co-labeling in a small fraction 
of cells. Scale, 20 μm. Adapted from Winchenbach et al. (2016). 
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(Figure 7 A). Conditional mutants progressively lost weight and had to be sacrificed 
17 to 18 days after tamoxifen induction. To assess whether this was due to a 
disturbed cholesterol homeostasis arising from Aldh1l1-CreERT2 transgene activity 
in peripheral organs such as liver (Winchenbach et al., 2016), serum cholesterol 
levels were measured at day 16 after tamoxifen injection. Indeed, total serum 
cholesterol concentration in these animals was reduced to 38.7 ± 7.6 % (n = 3, ± 
s.e.m.) compared to untreated wild type animals (Figure 7 C). In order to restore 
peripheral cholesterol levels mice received chow supplemented with 0.5% 
cholesterol (“chol chow”, Figure 7 A) which rescued weight loss and increased 
serum cholesterol levels (Figure 7 B, C). AstroSQS-tdTo animals on cholesterol 
chow appeared healthy and did not show any obvious behavioral abnormalities. 
 
 
Figure 7: Weight loss rescued by cholesterol diet. A) Scheme depicting the time course 
of tamoxifen injections and cholesterol treatment until analysis of the animals 16 days or 4 
weeks after the first tamoxifen injection. Animals received either normal chow or normal 
chow supplemented with 0.5% cholesterol (w/w) throughout the experiment starting 3 days 
before the first tamoxifen injection. B) Body weight of male animals assessed from the first 
day of tamoxifen injection until sacrifice of the animals. Data is expressed as mean weight ± 
s.d. of n = 3-9 animals. C) Total serum cholesterol concentration of male astroSQS-tdTo 
animals receiving normal chow or cholesterol supplemented chow (n = 3 animals each) 
analyzed on day 16 after the first tamoxifen injection compared to untreated male wild type 
animals (n = 9). Bars represent mean values with individual data points. Asterisks represent 






2.3.1 Do astrocytes survive that lack cell autonomous cholesterol synthesis? 
  
In order to answer the question whether mutant astrocytes survive, sagittal brain 
sections of astroSQS-tdTo mice receiving normal chow were immunolabeled for the 
astrocyte marker S100beta. Immunolabeled cells in the cortex exhibited the typical 
bushy morphology of protoplasmic astrocytes and were evenly distributed (Figure 8 
B, upper panel). Quantification revealed no difference in the density of S100beta 
positive astrocytes in the cortex of astroSQS-tdTo animals on normal chow 
compared to astro-tdTo controls (Figure 8 C). There was also no difference in 
morphology (Figure 8 B, lower panel) and density (Figure 8 C) of S100beta positive 
astrocytes in the cortex of astroSQS-tdTo animals on cholesterol chow compared 
to animals on normal chow or astro-tdTo controls. Furthermore, immunolabeling for 
Iba1 revealed that microglia exhibited a ramified morphology, equal distribution 
(Figure 9 A) and unchanged density (Figure 9 B) in the cortex of astroSQS-tdTo 
animals indicating absence of microglia activation. Together, these data suggest 
that astrocytes do not undergo apoptosis in astroSQS-tdTo animals. 
Figure 8: Loss of tdTomato signal in conditional mutants is not accompanied by 
astrocyte loss. A) Scheme depicting the time course of tamoxifen administration and 
duration of cholesterol chow treatment. Male and female astro-tdTo and astroSQS-tdTo 
animals on normal chow were analyzed 16 days after the first tamoxifen injection while 
astroSQS-tdTo animals receiving cholesterol supplemented chow were additionally 
analyzed 6 and 12 weeks after the first tamoxifen injection. B) Direct fluorescence of the 
Cre reporter tdTomato (red) and immunolabeling of the astrocyte marker S100beta (green) 
in cortical sections of astroSQS-tdTo animals receiving either normal chow (top row) or 
normal chow supplemented with 0.5% cholesterol (bottom row) 16 days after the first 
tamoxifen injection. Scales, 50 µm. C) Quantification of S100beta positive cells per mm2 in 
cortical layers II to IV in astro-tdTo mice on normal chow and astroSQS-tdTo animals 
receiving either normal or cholesterol chow at day 16 after the first tamoxifen injection. Cells 
were counted on 4 confocal pictures per animal. Bars represent mean values of n = 3 
animals per group with individual data points. D) Quantification of S100beta immunoreactive 
cells that also express the Cre reporter tdTomato in cortical sections of astro-tdTo animals 
on normal chow (+16 days) and astroSQS-tdTo animals on cholesterol chow (+16 days, +6 
and +12 weeks). Cells were counted on 4 confocal pictures per animal. Data are expressed 
as per cent of all S100beta immunoreactive cells per animal normalized to astro-tdTo 
animals (100 %). Bars represent mean values with individual data points (n = 3-4 animals 
per group). E) Maximum intensity projection of immunolabeling of NG2 (green), S100beta 
(cyan), direct tdTomato fluorescence (red) and labeling of EdU (white) and DAPI (blue) in 
the cortex of astroSQS-tdTo animals on cholesterol chow 16 days after the first tamoxifen 
injection. Arrow indicates an EdU positive NG2 cell. Scale, 20 µm. Asterisks represent 
significant differences with ***p < 0.001, ****p < 0.0001 (one-way ANOVA with Tukey’s 





2.3.2 What is the reason for reduced tdTomato signal in astroSQS-tdTo 
animals? 
 
Surprisingly, albeit unchanged astrocyte density, the fraction of S100beta positive 
astrocytes also positive for the Cre reporter tdTomato was reduced to 65 ± 5 % (n 
= 3, ± s.e.m.) in astroSQS-tdTo mice in cortex (Figure 8 D) and throughout the brain 
compared to astro-tdTo animals. This reduction remained unchanged between 16 
days and 12 weeks after tamoxifen injection indicating that this population of 
astrocytes is stable over time (Figure 8 D). In order to assess whether this reduction 
Figure 9: Absence of microglia activation in conditional mutants. A) Direct 
fluorescence of the Cre reporter tdTomato (red) and immunolabeling of the microglia marker 
Iba1 (green) in cortical sections of astroSQS-tdTo animals receiving either normal chow 
(top row) or normal chow supplemented with 0.5% cholesterol (bottom row) 16 days after 
the first tamoxifen injection. Scales, 50 µm. B) Quantification of Iba1 positive cells per mm2 
in cortical layers II to IV in astro-tdTo mice on normal chow and astroSQS-tdTo animals 
receiving either normal or cholesterol chow at day 16 after the first tamoxifen injection. Bars 
represent mean values of n = 3-4 animals per group with individual data points. 
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in tdTomato positive cells was due to insufficient tamoxifen administration the 
duration of tamoxifen treatment was increased from 5 to 10 consecutive days. 
However, prolonged tamoxifen treatment did not further increase the fraction of 
tdTomato/S100beta double-positive astrocytes in astroSQS-tdTo animals (data not 
shown). Did potentially non-recombined (tdTomato negative) astrocytes proliferate? 
Cortical astrocytes expand by local proliferation within the first postnatal week (Ge 
et al., 2012) and astrocyte turnover in the healthy adult brain is limited (Smart and 
Leblond, 1961; McCarthy and Leblond, 1988). However, in order to exclude this 
possibility astroSQS-tdTo animals (n = 3) on cholesterol chow were treated with 
EdU starting from the first day of tamoxifen administration for 16 days to label 
proliferating cells. Confocal microscopy revealed that the vast majority of EdU 
positive cells were glial cells expressing NG2, indicating that these were 
oligodendrocyte precursor cells (OPC) which are known to proliferate throughout 
adulthood (Rivers et al., 2008; Young et al., 2013). In agreement with previous 
reports (Karram et al., 2008), we found some cells that were positive for S100beta 
and NG2. However, proliferating S100beta/NG2 double-positive cells were not 
enriched in tdTomato negative territories (Figure 8 E). These data show that 
proliferation of potentially non-recombined (tdTomato negative) astrocytes could not 
account for the reduction in tdTomato positive cells in astroSQS-tdTo animals.  
 
2.3.3 Is squalene synthase successfully inactivated in astrocytes of 
conditional mutants? 
 
In order to address this question, first the expression of Fdft1 and Hmgcr, the rate-
limiting enzyme of cholesterol biosynthesis, as well as Apoe, the major 
apolipoprotein of the brain, was assessed by quantitative RT-PCR in the cortex of 
astroSQS-tdTo animals. Analysis revealed that the expression of Fdft1 and Hmgcr 
was unchanged in conditional mutants whereas the expression of Apoe was slightly 
but significantly increased (Figure 10 B). With respect to the reduction in tdTomato 
positive astrocytes (see above) we next investigated recombination efficiency of the 










Figure 10: Evaluation of knock-out efficiency in conditional mutants. A) Scheme 
depicting the time course of tamoxifen administration and duration of cholesterol chow 
treatment. Male and female astro-tdTo and astroSQS-tdTo animals on cholesterol chow 
were analyzed 16 days after the first tamoxifen injection. B) Quantitative RT-PCR analysis 
of dissected cortices of astro-tdTo and astroSQS-tdTo mice determining the expression of 
genes involved in cholesterol production (Hmgcr, Fdft1) and cholesterol transport (Apoe). 
Bars represent mean fold expression normalized to astro-tdTo animals with individual data 
points (n = 6-7). C) PCR for Fdft1 alleles (rec: recombined, flox: floxed, wt: wild type) on 
genomic DNA isolated from cortices of astroSQS (left), astroSQS-tdTo (middle) animals at 
day 16 after the first tamoxifen injection. The right lane shows the PCR of a mouse harboring 
one floxed and one recombined Fdft1 allele. D) Scheme depicting the time course of 
tamoxifen administration and duration of cholesterol chow treatment. Male (+16 days) and 
female (+29 days) SQS-flox and astroSQS animals on cholesterol chow were analyzed 16 
days or 29 days after the first tamoxifen injection (P35). E) Quantitative RT-PCR analysis of 
MACS-isolated cortical astrocytes of SQS-flox and astroSQS animals at day 16 and day 29 
after the first tamoxifen injection. Bars represent mean fold Fdft1 expression normalized to 
SQS-flox animals with individual data points (n = 3-5 animals). Asterisks represent 
significant differences with **p < 0.01, ***p < 0.001 (unpaired Student’s t-test). MACS 
isolation was performed together with Tim Düking. 
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Semi-quantitative PCR in the cortex suggested that the abundance of recombined 
Fdft1 alleles was reduced in astroSQS-tdTo animals compared to astroSQS animals 
without the tdTomato reporter (Figure 10 C) although variation was high (56 ± 6% 
of recombined alleles in astroSQS-tdTo animals compared to 100 ± 25% in 
astroSQS animals, n = 4 each, ± s.e.m.). Therefore, Fdft1 recombination was 
assessed more directly on cellular level by isolating astrocytes from the cortex of 
astroSQS animals without the tdTomato reporter 16 and 29 days after tamoxifen 
injection by magnetic-activated cell sorting (MACS). Quantitative RT-PCR of 
isolated astrocytes revealed that Fdft1 expression was strongly down-regulated in 
astroSQS animals compared to SQS-flox mice 16 days and even further 29 days 
after tamoxifen injection (Figure 10 E) indicating successful recombination in the 
majority of astrocytes. 
 
2.3.4 What are the electrophysiological properties of mutant astrocytes? 
 
Electrophysiological assessment of astrocytes allows determining cell viability and 
maturation status (Kafitz et al., 2008; Dallérac et al., 2013). Proliferation in response 
to injury altered electrophysiological properties of astrocytes in vitro reminiscent of 
immature glial cells (MacFarlane and Sontheimer, 1997). We therefore determined 
electrophysiologically whether lack of cholesterol synthesis affects astrocyte viability 
and maturation. In adult astro-tdTo animals the electrophysiological properties of 
tdTomato expressing cells are characteristic of viable mature astrocytes 
(Winchenbach et al., 2016). In astroSQS-tdTo animals the presence of floxed Fdft1 
and ROSA26-tdTomato alleles affected recombination leading to one population of 
astrocytes positive for tdTomato and one population without tdTomato expression 




In order to target all astrocytes in the cortex, acute forebrain slices of adult 
astroSQS-tdTo animals were stained with sulforhodamine 101 (SR101) (Figure 11 
Figure 11: Electrophysiological properties of astrocytes in conditional mutants. A) 
Fluorescence images of acute forebrain slices stained with sulforhodamine 101 (SR101) to 
label astrocytes. Cortical astrocytes that did not express the Cre reporter tdTomato (arrows, 
left panel) were identified by SR101 staining (arrows, right panel). Scale, 20 µm. B) Whole-
cell patch clamp recordings were performed of cortical SR101 positive astrocytes of wild 
type animals (gray, n = 13 cells), tdTomato/SR101 double-positive astrocytes (red, n = 11 
cells) as well as tdTomato negative/SR101 positive astrocytes (orange, n = 10 cells) of 
astroSQS-tdTo animals. The graph shows averaged I-V curves for each cell population 
(mean ± s.d.) in response to 200 ms voltage steps according to the voltage step protocol 
(inset). C) Resting membrane potential of astrocytes analyzed in B. Bars represent mean 
values with individual data points. D) Membrane resistance of astrocytes analyzed in B. 
Bars represent mean values with individual data points. 
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A). SR101 is a well-established marker to label astrocytes in various brain regions 
including cortex without altering the electrophysiological properties of the cells 
(Nimmerjahn et al., 2004; Kafitz et al., 2008; Schnell et al., 2012). Whole-cell patch 
clamp recordings revealed that both tdTomato positive and tdTomato negative 
astrocytes in astroSQS-tdTo animals did not differ from astrocytes of wild type 
animals in their response to varying voltage steps (p = 0.6234 and p = 0.7676, of 
max. inward and outward currents, respectively as assessed by one-way ANOVA) 
and displayed almost linear current/voltage relationships representative of mature 
astrocytes (Figure 11 B). There was also no difference in resting membrane 
potential (Figure 11 C) and membrane resistance (Figure 11 D) between the cell 
populations indicating that all cells resembled viable mature astrocytes. These data 
indicate that lack of squalene synthase does not affect the electrophysiological 
properties of mature astrocytes. 
 
2.3.5 Does lack of squalene synthase in astrocytes affect blood-brain barrier 
integrity? 
 
Astrocytes cover nearly 100 % of brain microvessels (Mathiisen et al., 2010) and 
are important for maintenance of blood-brain barrier (BBB) function including 
regulation of BBB integrity via ApoE (Bell et al., 2012). In order to assess whether 
lack of SQS impairs astrocyte function to maintain BBB integrity, brain water content 
as a measure of edema formation and the extent of Evans Blue (EB) extravasation 
was analyzed in the brains of astroSQS animals. Evans Blue is a fluorescent dye 
that binds serum albumin and a widely used marker to assess BBB integrity. As a 
positive control of assay sensitivity data of cuprizone fed animals are shown that 








In astroSQS animals brain water content and the amount of extravasated EB were 
unaffected 16 and 103 days after tamoxifen injection compared to wild type animals 
and in contrast to cuprizone fed animals that display edema formation and BBB 
dysfunction (Figure 12 B, C, D and Berghoff et al., 2017a; 2017b). To assess 
whether peripheral cholesterol enters the brain, extravasation of the fluorescent 
cholesterol derivative bodipy-cholesterol was determined in the brains of astroSQS 
animals. After intraperitoneal injection slightly but significantly increased 
extravasation of bodipy-cholesterol was detected in astroSQS animals (Figure 12 
D). Dysregulation of the water channel aquaporin 4 (AQP4) expressed on astroglial 
endfeet occurs during edema formation and increased Aqp4 abundance indicates 
BBB impairment (Abbott et al., 2005). In younger astroSQS animals Aqp4 
Figure 12: Blood-brain barrier integrity in conditional mutants. A) Scheme depicting 
the time course of tamoxifen administration and duration of cholesterol chow treatment. Wild 
type and astroSQS animals on cholesterol chow were analyzed 16 and 103 days after the 
first tamoxifen injection. As a positive control, data of cuprizone-fed animals that exhibit 
blood-brain barrier impairment are shown. Cuprizone data adapted from Berghoff et al., 
2017a and Berghoff et al., 2017b. B) Brain water content of astroSQS animals 16 and 103 
days after the first tamoxifen injection as well as brain water content of wild type animals fed 
a cuprizone diet for 5 weeks (Berghoff et al., 2017a). Bars represent mean values with 
individual data points normalized to corresponding control animals (16d: astroSQS, n = 5, 
wild type control, n = 3 animals; 103d: astroSQS, n = 5, wild type control, n = 5 animals; 
cuprizone: n = 6, control, n = 5 animals). C) Evans blue (EB) extravasation in brains of 
astroSQS animals 16 and 103 days after the first tamoxifen injection as well as EB 
extravasation of wild type animals fed a cuprizone diet for 5 weeks (Berghoff et al., 2017a). 
Bars represent mean values with individual data points normalized to corresponding control 
animals (16d: astroSQS, n = 5, wild type control, n = 5 animals; 103d: astroSQS, n = 5, wild 
type control, n = 5 animals; cuprizone: n = 6, control, n = 5 animals). D) Extravasation of 
bodipy-cholesterol in brains of astroSQS animals 103 days after the first tamoxifen injection 
as well as of wild type animals fed a cuprizone diet for 5 weeks (Berghoff et al., 2017b). 
Bars represent mean values with individual data points normalized control animals (103d: 
astroSQS, n = 5, cuprizone: n = 6, wild type control, n = 6 animals). E) Scheme depicting 
the time course of tamoxifen administration and duration of cholesterol chow treatment. Wild 
type and astroSQS animals on cholesterol chow were analyzed 29 days after the first 
tamoxifen injection. F) Quantitative RT-PCR analysis of dissected hippocampi of wild type 
(n = 5 animals) and astroSQS (n = 4 animals) 29 days after the first tamoxifen injection. 
Bars represent mean fold Aqp4 expression normalized to wild type animals with individual 
data points. G) Immunolabeling of Aquaporin4 in CA1 (upper row) and cortex (lower row) of 
wild type and astroSQS animals. Scales, 50µm. H) Quantification of Aquaporin4 
immunoreactivity in CA1 and cortex of wild type (n = 4) and astroSQS (n = 4) animals. Bars 
represent mean Aquaporin4 positive area (%) with individual data points. Asterisks 
represent significant differences compared to corresponding controls with *p < 0.05, **p < 
0.01, ****p < 0.0001 (unpaired Student’s t-test). Analysis of cuprizone-fed animals was 
performed by Stefan Berghoff (Berghoff et al., 2017a; 2017b). Analysis of EB and bodipy-
cholesterol extravasation (C and D) was performed together with Stefan Berghoff: Jan 
Winchenbach performed tamoxifen injections, tissue preparation and lyophilization. Stefan 
Berghoff performed tracer injection, formamide extraction and tracer quantification. 
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expression was increased in the hippocampus compared to wild type mice (Figure 
12 E, F) but protein levels were unaltered in the CA1 region of the hippocampus and 
cortex as assessed by immunolabeling (Figure 12 G, H). Together, these data 
indicate that astroSQS animals do not display BBB breakdown but peripheral 
cholesterol might cross the BBB at low levels. 
 
2.4 Does lack of astrocytic cholesterol synthesis affect Alzheimer’s disease 
pathology? 
 
The successful targeting of the majority of CNS astrocytes and the lack of 
pathological changes render astroSQS mutants a useful tool to study the effect of 
astrocyte-specific loss of cholesterol synthesis on Alzheimer’s disease (AD) 
pathology. The 5xFAD mouse model of AD displays progressive deposition of 
amyloid-β peptides (Aβ) starting in cortex and subiculum of the hippocampus at 
around 2 months of age accompanied by astrocyte and microglia activation (Oakley 
et al., 2006). Memory deficits become apparent at 6 months and progress with age 
accompanied by neuron loss in cortical layer V at 12 months (Jawhar et al., 2012).  
 
2.4.1 Are cholesterol homeostasis and BBB integrity altered in 5xFAD 
animals? 
 
In order to assess whether cholesterol homeostasis is altered in 5xFAD animals, the 
expression of the major genes involved in cholesterol synthesis (Figure 13 A), 
transport (Figure 13 B), uptake (Figure 13 C) and excretion (Figure 13 D) was 
analyzed in the hippocampus of 5xFAD animals at postnatal day 64 (P64). 
Expression levels were unchanged compared to age and sex-matched wild type 
animals except for a slight reduction in the expression of apolipoprotein J (also 
known as clusterin, Clu). To analyze whether peripheral cholesterol could potentially 
affect brain cholesterol homeostasis, we next assessed BBB integrity in 5xFAD 
animals. There was no change in brain water content and only minor increase in 
extravasated EB and sodium fluorescein (NaFl) during advanced disease in 4.5 





Figure 13: Cholesterol homeostasis and BBB integrity in 5xFAD animals. Male wild type 
and 5xFAD animals received tamoxifen injections on 5 consecutive days starting at P35 and 
were treated with 0.5% cholesterol chow until analysis at day 29 after the first tamoxifen 
injection (A-D). Quantitative RT-PCR analysis of dissected hippocampi of wild type and 
5xFAD animals was performed to assess expression of genes involved in cholesterol 
production (A), transport (B), uptake (C) and excretion (D). Bars represent mean fold 
expression normalized to wild type animals with individual data points (n = 4-5). Assessment 
of BBB integrity was performed in female 4.5 month old 5xFAD and age-matched female wild 
type animals on normal chow without tamoxifen administration. E) Brain water content of wild 
type and 5xFAD animals. Bars represent mean values with individual data points normalized 
to wild type animals (wild type, n = 4, 5xFAD, n = 5). F) Evans blue (EB) extravasation in 
brains of wild type and 5xFAD animals. Bars represent mean values with individual data 
points normalized to wild type animals (wild type, n = 4, 5xFAD, n = 5). G) Extravasation of 
sodium fluorescein (NaFl) in brains of wild type and 5xFAD animals. Bars represent mean 
values with individual data points normalized control animals (wild type, n = 4, 5xFAD, n = 5). 
Asterisks represent significant differences with *p < 0.05 (unpaired Student’s t-test). Analysis 
of EB and NaFl extravasation (F and G) was performed together with Stefan Berghoff: Jan 
Winchenbach performed tissue preparation and lyophilization. Stefan Berghoff performed 
tracer injection, formamide extraction and tracer quantification. 
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2.4.2 Conditional inactivation of squalene synthase in 5xFAD animals 
 
In order to inactivate squalene synthase in 5xFAD animals, astroSQS mice were 
crossed with 5xFAD mice generating offspring with the genotype Aldh1l1-
CreERT2*5xFAD*Fdft1flox/flox, hereafter termed astroSQS-5xFAD mutants. Age and 
sex-matched wild type, astroSQS and 5xFAD animals served as controls. All 
animals received 0.5% cholesterol chow and were injected with tamoxifen at P35 
and analyzed 29 days later (Figure 14 A) because preliminary experiments indicated 
early changes in astroSQS-5xFAD mutants (data not shown). Due to the different 
extent of amyloid pathology (Oakley et al., 2006) male and female mice were 
analyzed separately. Conditional astroSQS-5xFAD mutants were healthy with 
normal body weight (Figure 14 B, C) and did not show any obvious behavioral 
abnormalities. There was also no change in serum cholesterol concentration in 






2.4.3 Does lack of astrocytic cholesterol synthesis affect cerebral β-
amyloidosis? 
 
In 5xFAD mice Aβ deposition starts in the subiculum and cortical layers IV to VI at 
around 2 months of age (Oakley et al., 2006). To assess Aβ deposition in astroSQS-
5xFAD mice serial sections throughout the hippocampus were immunolabeled using 
a pan Aβ antibody (218211, clone NT244). Microscopy revealed extracellular Aβ 
deposits as well as some intracellular immunoreactivity restricted to the subiculum 
of the hippocampus (data not shown). Quantification showed reduced Aβ 
immunoreactivity throughout the hippocampus in astroSQS-5xFAD mice (0.44 ± 
0.09 % Aβ positive area) compared to 5xFAD controls (0.56 ± 0.05 %, n = 5-6 
animals each, ± s.e.m.) without reaching statistical significance. In order to quantify 
Aβ deposition more directly, hippocampal sections were immunolabeled with an 
Aβ42 specific antibody (44-344, ThermoFisher) that detected extracellular deposits 
without intracellular staining (Figure 15 A, B). Quantification revealed significantly 
reduced Aβ42 deposition in the subiculum of male astroSQS-5xFAD mice compared 
to 5xFAD controls (Figure 15 C). Non-plaque oligomeric Aβ species are increased 
in AD patients (McDonald et al., 2012) and accumulating evidence indicate Aβ 
oligomers in neurotoxicity and cognitive decline (reviewed in Aguzzi and O'Connor, 
2010). Therefore, water- (TBS-soluble) and detergent-soluble (SDS-soluble) Aβ40 
and Aβ42 peptides were quantified in the hippocampus of astroSQS-5xFAD 
animals. There was no difference in the concentration of TBS-soluble and SDS-
soluble Aβ peptides in male (Figure 15 D, F) and female (Figure 15 E, G) astroSQS-
Figure 14: Body weight and serum cholesterol unchanged in astroSQS-5xFAD 
mutants. A) Scheme depicting the time course of tamoxifen administration and duration of 
cholesterol chow treatment. Wild type, astroSQS as well as 5xFAD and compound 
astroSQS-5xFAD mutants were analyzed 29 days after the first tamoxifen injection. Male 
and female mice were analyzed separately. Body weight (g) of male (B) and female (C) 
mice was not different in all experimental groups analyzed. Bars represent mean values 
with individual data points (wild type: male, n = 5, female, n = 11; astroSQS: male, n = 9, 
female, n = 10; 5xFAD: male, n = 15, female, n = 24; astroSQS-5xFAD: male, n = 12, female, 
n = 13). Total serum cholesterol concentration (mg/dl) of male (D) and female (E) mice was 
not different in all experimental groups analyzed. Bars represent mean values with individual 
data points (wild type: male, n = 5, female, n = 8; astroSQS: male, n = 5, female, n = 7; 




5xFAD mice compared to 5xFAD controls. These findings show that albeit soluble 





2.4.4 Is the reduction in Aβ deposition due to increased clearance by glial 
cells? 
 
Neuroinflammation with activation of astrocytes and microglia is a common feature 
in the brains of AD patients and mouse models of AD and both cell types are able 
to degrade Aβ (reviewed in Solito and Sastre, 2012; Ferrer, 2017). ApoE promotes 
the degradation of Aβ by astrocytes and microglia in vitro (Koistinaho et al., 2004; 
Jiang et al., 2008). Promoting lipidation of ApoE increased Aβ clearance by 
microglia in vitro and reduced Aβ deposition in vivo (Jiang et al., 2008). Histological 
analysis of Iba1 immunoreactivity is a widely used method to assess microglia 
activation in 5xFAD mice (Oakley et al., 2006; Katsouri and Georgopoulos, 2011; 
Wang et al., 2015; Marsh et al., 2016). Similar to Iba1 expression, increase in GFAP 
immunoreactivity has been demonstrated in vicinity of Aβ deposits and with disease 
progression in 5xFAD mice indicating astrogliosis (Oakley et al., 2006; Katsouri and 
Georgopoulos, 2011; Hüttenrauch et al., 2015). In order to assess astroglial and 
microglial responses in astroSQS-5xFAD mice, hippocampal sections were 
immunolabeled for GFAP and Iba1. As expected, hypertrophic microglia with 
enlarged cell bodies were found in the immediate vicinity of Aβ deposits (Figure 16 
A, arrows) in the subiculum whereas hypertrophic astrocytes were either found 
closely associated with or located in proximity to plaques (Figure 16 A). 
Figure 15: Compound astroSQS-5xFAD mutants exhibit reduced Aβ42 deposition in 
the subiculum. A) Representative pictures of Aβ42 immunolabeling of the lateral 
hippocampus (sagittal sections) of male 5xFAD (left panel) and astroSQS-5xFAD (right 
panel) animals at P64 (29 days after the first tamoxifen injection) with the subiculum outlined 
as dashed line (right panel). Scale, 300 µm. B) Aβ42 immunolabeling in the subiculum of 
5xFAD and astroSQS-5xFAD animals at locations indicated in (A). Scale, 40 µm. C) 
Quantification of Aβ42 deposition in the subiculum of male 5xFAD and astroSQS-5xFAD 
animals at P64. Bars represent mean Aβ42 positive area (%) with individual data points 
(5xFAD, n = 3, astroSQS-5xFAD, n = 8). TBS-soluble (D and E) and SDS-soluble (F and 
G) Aβ40 and Aβ42 peptides were quantified in the hippocampus of male (D and F) and 
female (E and G) 5xFAD and astroSQS-5xFAD mice at P64 using an 
electrochemiluminescene-linked immunoassay. Bars represent mean values normalized to 
total protein concentration with individual data points (5xFAD: male, n = 3, female, n = 3-5; 
astroSQS-5xFAD: male, n = 4-5, female, n = 3-5). Asterisks represent significant 







Quantification revealed elevated Iba1 immunoreactivity in the subiculum of 5xFAD 
mice which was significantly increased in astroSQS-5xFAD animals compared to 
wild type (Figure 16 B). Although GFAP immunoreactivity was increased locally at 
plaques in 5xFAD and astroSQS-5xFAD animals, quantification did not reveal 
significant changes throughout the subiculum compared to wild type and astroSQS 
animals (Figure 16 C). Quantitative RT-PCR analysis in the hippocampus showed 
also no differences in the expression of Gfap while Aqp4 expression was increased 
in astroSQS mice but not in astroSQS-5xFAD mice compared to wild type animals 
(Figure 16 D). Analysis of genes involved in microglia activation and homeostasis 
revealed increased expression of the gene encoding Iba1 (allograft inflammatory 
factor 1, Aif1) in 5xFAD mice as previously reported (Landel et al., 2014) but also in 
astroSQS mice (Figure 16 E). Expression of P2ry12 (purinergic receptor P2Y12), a 
homeostatic microglia marker that is down-regulated upon cellular activation in 
response to CNS injury (Haynes et al., 2006) and in disease-associated microglia 
in 5xFAD mice (Keren-Shaul et al., 2017) was significantly increased in astroSQS 
and astroSQS-5xFAD animals compared to wild type animals (Figure 16 E). In order 
to assess microglial changes in more detail, the expression of genes involved in 
microglia activation and phagocytosis as well as genes involved in increased risk 
Figure 16: Astroglial and microglial response in compound astroSQS-5xFAD 
mutants. A) Co-immunolabeling of microglia (Iba1, red), astrocytes (GFAP, green) and Aβ 
(Aβ38/40/42, labeled with pan anti-Aβ antibody, blue) with location of Aβ deposits indicated 
(arrows) in the subiculum of male astroSQS-5xFAD mice at P64. Scale, 50µm. B) 
Quantification of Iba1 positive microglia in the subiculum of male wild type (n = 3), 5xFAD 
(n = 5) and astroSQS-5xFAD (n = 6) animals at P64. Bars represent mean Iba1 positive 
area (%) with individual data points. C) Quantification of GFAP positive astrocytes in the 
subiculum of male wild type (n = 4), astroSQS (n = 4), 5xFAD (n = 4) and astroSQS-5xFAD 
(n = 6) animals at P64. Bars represent mean GFAP positive area (%) with individual data 
points. Quantitative RT-PCR analysis of dissected hippocampi of male wild type (n = 4-5), 
astroSQS (n = 3-4), 5xFAD (n = 4-5) and astroSQS-5xFAD (n = 5-6) animals at P64 
determining the expression of genes involved in astrocyte activation and function (D), 
microglia activation and homeostasis (E), as well as genes involved in microgliosis, 
phagocytosis, risk for Alzheimer’s disease (F-H) and degradation of Aβ (I). Bars represent 
mean fold expression normalized to wild type animals (set to 1, dashed line) with individual 
data points. Asterisks represent significant differences with *p < 0.05, **p < 0.01, ****p < 
0.0001, hash symbols denote significant difference relative to wild type controls with #p < 
0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 (one-way ANOVA with Tukey’s multiple 
comparison test). Immunohistochemical analysis (A-C) was performed together with Borja 
Gómez Ramos: Jan Winchenbach performed tamoxifen injections, tissue preparation and 
fixation as well as quantification. Borja Gómez Ramos performed most of the 
immunolabeling and microscopy. 
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for AD was quantified. Expression of several genes was found to be unchanged 
including Lamp2 (lysosome-associated membrane protein 2, also known as Mac-
3), Timp2 (tissue inhibitor of metalloproteinases 2), Ctsd (cathepsin D) and Tspo 
(translocator protein, Figure 16 F). The expression of Lpl (lipoprotein lipase), an 
enzyme involved in lipid metabolism found in activated microglia near Aβ plaques in 
5xFAD mice and AD patients (Keren-Shaul et al., 2017), was increased in astroSQS 
mice but not in 5xFAD and astroSQS-5xFAD mice (Figure 16 G). Due to its role in 
the risk for AD and Aβ clearance (reviewed in Ulrich et al., 2017) the expression of 
Trem2 (triggering receptor expressed on myeloid cells 2), a lipid sensor expressed 
by microglia, and its signaling adaptor DAP12 (encoded by the Tyrobp gene) were 
analyzed. Expression of Trem2 was found to be significantly increased in astroSQS-
5xFAD mice compared to 5xFAD mice while the expression of Tyrobp was elevated 
both in astroSQS-5xFAD and 5xFAD animals (Figure 16 G). The strongest increase 
in expression level both in 5xFAD and astroSQS-5xFAD mice was detected for the 
lysosomal protease inhibitor cystatin F (encoded by Cst7) in line with its increase in 
plaque-associated microglia in 5xFAD mice (Ofengeim et al., 2017). However, 
expression was not different in astroSQS-5xFAD compared to 5xFAD animals 
(Figure 16 H). Next, the expression of Aβ degrading enzymes was analyzed in 
astroSQS-5xFAD animals. As previously reported for 5xFAD animals at similar age 
the expression of Mme (encoding neprilysin) was reduced compared to wild type 
mice (Py et al., 2014; Hüttenrauch et al., 2015) but unchanged between 5xFAD and 
astroSQS-5xFAD animals (Figure 16 I). There was also no difference in the 
expression of Ide (insulin-degrading enzyme), Ece1 and Ece2 (endothelin-
converting enzyme 1 and 2) between 5xFAD and astroSQS-5xFAD mice (Figure 16 
I). Together these data show, that changes in astroglial and microglial responses 
between 5xFAD and astroSQS-5xFAD animals so far seem to be limited to Trem2 
expression. 
 
2.4.5 Is the cholesterol metabolism altered in astroSQS-5xFAD mutants? 
 
To assess the effect of SQS inactivation in astrocytes on brain cholesterol 
metabolism in wild type and 5xFAD animals, hippocampal expression of genes 
involved in cholesterol production, transport, secretion and uptake was analyzed by 
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quantitative RT-PCR. The expression of the major enzymes regulating cholesterol 
production were unchanged in all experimental groups (Figure 17 A). The 
expression of Apoe was variable between individual animals and unchanged across 
genotypes, while Clu was slightly down-regulated in 5xFAD and astroSQS-5xFAD 
mice compared to astroSQS but not to wild type animals (Figure 17 B). There were 
no changes in mRNA levels of genes involved in cellular cholesterol excretion 
(Figure 17 C) and uptake of cholesterol (Figure 17 D). Furthermore, western blot 
analysis revealed no changes in ApoE protein abundance in the hippocampus 
across genotypes (Figure 17 E, F). These data suggest that lack of SQS in 
astrocytes does not lead to drastic changes in tissue cholesterol homeostasis in wild 
type or 5xFAD animals. 
 
2.4.6 Is APP processing to generate Aβ altered in astroSQS-5xFAD mutants? 
 
In 5xFAD mice expression of mutant human APP and PS1 and therefore Aβ 
generation is directed to neurons by the Thy1 promoter (Oakley et al., 2006). 
Neuronal amyloidogenic processing of APP in endosomes is affected by cellular 
cholesterol content in vitro (Simons et al., 1998; Wahrle et al., 2002; Schneider et 
al., 2008) and direct interaction of APP and cholesterol could enhance β-secretase 
mediated Aβ production in cholesterol-rich lipid rafts (Barrett et al., 2012). We 
therefore asked whether lack of astrocytic cholesterol support to neurons could 
modulate neuronal cholesterol content that, in turn could affect APP processing. As 
expected, expression of murine App was not affected by SQS inactivation or 5xFAD 
transgene expression (Figure 18 A). In contrast to previous reports (Zhao et al., 
2007) expression of Bace1 (beta-site APP-cleaving enzyme 1), the major β-
secretase cleaving APP (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; 
Yan et al., 1999) was slightly reduced in 5xFAD compared to wild type animals 







Bace2, a Bace1 homologue was found to also cleave APP at the β-site but more 
prominently at the α-site (Hussain et al., 2000; Yan et al., 2001). Overexpression of 
Bace2 reduced Aβ production in vitro and Bace2 could act as an Aβ degrading 
enzyme (Sun et al., 2006; Abdul-Hay et al., 2012). Surprisingly, Bace2 expression 
was significantly reduced in 5xFAD compared to astroSQS-5xFAD mice (Figure 18 
A). Next, the abundance of APP C-terminal fragments resulting from β-secretase 
(C99 or β-CTF) and α-secretase cleavage (C83 or α-CTF) of APP were analyzed in 
the hippocampus of 5xFAD and astroSQS-5xFAD animals (Figure 18 B). The 
abundance of C99 and C83 fragments was unchanged in male astroSQS-5xFAD 
mice whereas C99 abundance was significantly elevated in female astroSQS-
5xFAD animals compared to 5xFAD mice (Figure 18 C, D). However, despite 
significant variation between animals the abundance of C83 was also increased in 
female astroSQS-5xFAD mice resulting in an unchanged C83/C99 ratio (Figure 18 
D, E). Together these findings suggest that lack of astrocytic cholesterol production 
does not affect neuronal APP processing. In summary, inactivation of cholesterol 
synthesis in astrocytes resulted in reduced Aβ42 deposition in the subiculum without 
obvious changes in tissue cholesterol homeostasis or APP processing. Whether 
lack of neuronal cholesterol synthesis differently affects APP processing and Aβ 
deposition is addressed in the next paragraph. 
 
Figure 17: Cholesterol homeostasis is unchanged in compound astroSQS-5xFAD 
mutants. Quantitative RT-PCR analysis of dissected hippocampi of male wild type (n = 4-
5), astroSQS (n = 4), 5xFAD (n = 5) and astroSQS-5xFAD (n = 5-6) animals at P64 was 
performed to assess expression of genes involved in cholesterol production (A), transport 
(B), uptake (C) and excretion (D). Bars represent mean fold expression normalized to wild 
type animals (set to 1, dashed line) with individual data points. Asterisks represent 
significant differences with *p < 0.05 (one-way ANOVA with Tukey’s multiple comparison 
test). E) Western blot analysis for Apolipoprotein E (ApoE) of dissected hippocampi of male 
wild type (n = 4), astroSQS (n = 3), 5xFAD (n = 3) and astroSQS-5xFAD (n = 4) animals at 
P64. Wt, wild type; kDa, kilodalton. F) Densitometric quantification of ApoE bands 
normalized to Actin loading control shown in (E). Bars represent mean ApoE protein 






Figure 18: Assessment of APP processing in compound astroSQS-5xFAD mutants. 
A) Quantitative RT-PCR analysis of dissected hippocampi of male wild type (n = 4-5), 
astroSQS (n = 4), 5xFAD (n = 5) and astroSQS-5xFAD (n = 6) animals at P64 was 
performed to assess expression of murine amyloid precursor protein (App) and APP protein 
processing enzymes (Bace1, Bace2). Bars represent mean fold expression normalized to 
wild type animals (set to 1, dashed line) with individual data points. Asterisks represent 
significant differences with *p < 0.05, **p < 0.01, hash symbols denote significant difference 
relative to wild type controls with #p < 0.05, ##p < 0.01 (one-way ANOVA with Tukey’s 
multiple comparison test). B) Western blot analysis of APP C-terminal fragments C99 and 
C83 of dissected hippocampi (SDS-soluble protein fraction) of male 5xFAD and astroSQS-
5xFAD animals at P64. KO, knock-out (astroSQS-5xFAD); Ctrl, control (5xFAD); kDa, 
kilodalton. Densitometric quantification of C99 (C) and C83 (D) bands normalized to GAPDH 
loading control of male and female 5xFAD (male, n = 3, female, n = 5) and astroSQS-5xFAD 
(male, n = 5, female, n = 5) animals. Bars represent mean C99 (C) and C83 (D) protein 
abundance normalized to 5xFAD animals with individual data points. E) Ratio of C83/C99 
protein abundance shown in (C) and (D) normalized to 5xFAD animals. Bars represent 
mean C83/C99 ratio with individual data points. 
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2.5 Does lack of neuronal cholesterol synthesis affect Aβ production and 
deposition? 
 
Reduction in neuronal cholesterol content diminished Aβ production in vitro (Simons 
et al., 1998; Wahrle et al., 2002), but the role of neuronal cholesterol synthesis in 
Aβ generation in vivo is largely unknown. Inactivation of cholesterol synthesis in all 
neural cells or embryonically in forebrain projection neurons led to neonatal death 
of mutant mice (Saito et al., 2009; Fünfschilling et al., 2012). However, postnatal 
loss of cholesterol biosynthesis in forebrain projection neurons is fully compensated 
by increased synthesis and enhanced transfer of cholesterol via ApoE lipoproteins 
by other cells including astrocytes (Fünfschilling et al., 2012). In these mice, 
hereafter termed neuroSQS mutants, recombination in the majority of projection 
neurons (Fünfschilling et al., 2012) including cortex and hippocampus is driven by 
the CaMKIIα-Cre line (Minichiello et al., 1999) starting from postnatal day 5 (P5, 
Brinkmann et al., 2008). The lack of CNS pathology and the targeting of neurons in 
regions of initial Aβ deposition in 5xFAD mice (Oakley et al., 2006) render neuroSQS 
mice a suitable model to investigate the role of neuronal cholesterol synthesis during 
AD pathology. Conditional mutants with the genotype CaMKIIα-
Cre*5xFAD*Fdft1flox/flox, hereafter termed neuroSQS-5xFAD mutants, and controls 
were analyzed at P70 (Figure 19 A) because preliminary experiments indicated an 
early effect in Aβ deposition (data not shown). Conditional neuroSQS-5xFAD mice 
were healthy despite slightly reduced body weight in male mice (Figure 19 B) and 





Figure 19: Phenotypic assessment of compound neuroSQS-5xFAD mutants. A) 
Scheme depicting the time point of analysis of wild type, neuroSQS as well as 5xFAD and 
compound neuroSQS-5xFAD mutants receiving normal chow. Male and female mice were 
analyzed separately. Body weight (g) of male (B) and female (C) mice. Bars represent mean 
values with individual data points (wild type: male, n = 8, female, n = 2; neuroSQS: male, n = 
5, female, n = 3; 5xFAD: male, n = 14, female, n = 5; neuroSQS-5xFAD: male, n = 4, female, 
n = 6). D) Total serum cholesterol concentration (mg/dl) of male and female 5xFAD and 
neuroSQS-5xFAD mice. Bars represent mean values with individual data points (5xFAD: 
male, n = 7, female, n = 5; neuroSQS-5xFAD: male, n = 2, female, n = 3). E) Aβ42 
immunolabeling in the subiculum of female 5xFAD and neuroSQS-5xFAD animals. Scale, 
40µm. F) Quantification of Aβ42 deposition in the subiculum of female 5xFAD and neuroSQS-
5xFAD animals. Bars represent mean Aβ42 positive area (%) with individual data points 
(5xFAD, n = 3, astroSQS-5xFAD, n = 4). G) Western blot analysis of APP C-terminal 
fragments C99 and C83 of dissected hippocampi (SDS-soluble protein fraction) of male 
5xFAD and neuroSQS-5xFAD animals. KO, knock-out (neuroSQS-5xFAD); Ctrl, control 
(5xFAD); kDa, kilodalton. Asterisks represent significant differences with *p < 0.05 (one-way 




Serum cholesterol measurements suggested no changes in total cholesterol 
concentration in male and female mice although the number of animals investigated 
was low (Figure 19 D). Quantification of Aβ42 deposition in the subiculum revealed 
no difference between female 5xFAD and neuroSQS-5xFAD mice (Figure 19 F). In 
order to assess the effect of neuronal loss of SQS on APP processing, the 
abundance of APP C-terminal fragments C99 and C83 was analyzed in the 
hippocampus by western blot. Analysis of two male (Figure 19 G) and two female 
(data not shown) neuroSQS-5xFAD mice and two corresponding 5xFAD controls 
did not suggest major changes in APP processing. So far, loss of neuronal 
cholesterol synthesis does not seem to induce major changes in the generation and 
deposition of Aβ peptides. Future experiments will show whether, similar to 
astroSQS-5xFAD mutants, cholesterol manipulation affects Aβ deposition in male 























3.1 Efficient targeting of astrocytes in Aldh1l1-CreERT2 mice 
 
Analysis of gene function in adult astrocytes has been limited by the lack of 
transgenic mouse lines that express inducible Cre recombinase in the majority of 
cortical and spinal cord astrocytes. The first aim of this study was to assess 
efficiency and specificity of CreERT2 mediated recombination in a newly generated 
Aldh1l1-CreERT2 BAC transgenic mouse line (Winchenbach et al., 2016). Analysis 
of CreERT2 mediated tdTomato reporter expression revealed efficient targeting of 
astrocytes throughout the adult brain and in the spinal cord. Quantification using the 
astrocyte marker S100beta revealed that the vast majority (>90%) of cortical 
astrocytes are targeted. Efficiency of reporter expression in the cortex was 
confirmed in mice that also express Egfp mediated by the Aldh1l1-Egfp BAC 
transgene (Heintz, 2004). Furthermore, the majority of ACSA2 positive astrocytes 
expressed the Cre reporter tdTomato in isolated astrocytes analyzed by FACS. In 
our hands, quantification of CreERT2 mediated recombination using a different 
reporter line (Srinivas et al., 2001) showed that only two thirds of cortical astrocytes 
were recombined indicating that the tdTomato reporter is more sensitive. Recently, 
the same tdTomato reporter line (Madisen et al., 2010) was used to demonstrate 
recombination of astrocytes in Slc1a3-CreERT2 (Mori et al., 2006) and GFAP-
CreERT2 (Hirrlinger et al., 2006) mice (Jahn et al., 2015). The presented data 
suggest tdTomato recombination in the minority of cortical astrocytes in GFAP-
CreERT2 animals while tdTomato expression appeared patchy in the cortex of 
Slc1a3-CreERT2 animals. Together, these data show that cortical astrocytes are 
efficiently targeted in adult Aldh1l1-CreERT2 mice, which had not been possible 
with previously generated lines (Hirrlinger et al., 2006; Mori et al., 2006; Slezak et 
al., 2007). The results of the current study are in agreement with data reported by 
an independent group using a different Aldh1l1-CreERT2 mouse line (Srinivasan et 
al., 2016).  
In Aldh1l1-CreERT2 animals, reporter recombination was virtually absent in 
neurons and microglia. However, tdTomato expression was found in a subset of 
cells expressing the oligodendrocyte lineage marker Olig2 and in some NG2 
expressing oligodendrocyte precursor cells (OPC). However, the Cre reporter was 
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virtually absent in CAII positive mature oligodendrocytes 12 days and 27 weeks after 
tamoxifen administration. This indicates that the few tdTomato expressing OPC do 
not give rise to mature oligodendrocytes in adult animals. Future experiments are 
required to assess whether this is also the case when recombination is induced 
before maximal oligodendrocyte differentiation during myelination. In the Aldh1l1-
CreERT2 line generated by Srinivasan et al., transcriptome profiling revealed 
expression of Olig1, Olig2, CNP and CAII but not NG2 in targeted cortical astrocytes 
(Srinivasan et al., 2016). Whether these differences are due to the different 
experimental approaches employed remains to be determined. In summary, the 
newly generated Aldh1l1-CreERT2 mouse line characterized in the present study is 
a valuable tool to target astrocytes at desired time points. 
 
3.2 Inactivation of cholesterol synthesis in adult astrocytes 
 
The role of astrocytic cholesterol synthesis in brain cholesterol metabolism and 
function in vivo is incompletely understood. Targeting of lipid and cholesterol 
synthesis in astrocytes already during development has led to detrimental effects in 
brain development. Genetic inactivation of the sterol sensor SCAP in astrocytes 
resulted in severe brain defects including microcephaly and reduction of cholesterol 
and fatty acid synthesis leading to premature death (Camargo et al., 2012). Mutant 
mice lacking Srebf2, a transcriptional regulator of cholesterol and lipid synthesis, in 
astrocytes survived but showed microcephaly and impaired memory and motor 
defects (Ferris et al., 2017). To address the role of astrocytic cholesterol in adult 
animals, we inactivated cholesterol biosynthesis by crossing SQS-flox mice (Saher 
et al., 2005) with the newly generated Aldh1l1-CreERT2 mouse line followed by 
tamoxifen administration at 8 weeks of age. We found that peripheral cholesterol 
supply in the chow was required to rescue dysregulation of serum cholesterol and 
weight loss, likely attributed to transgene activity in the liver (Winchenbach et al., 
2016). Mutant mice on cholesterol chow were healthy and lacked any obvious 
behavioral abnormalities. Astrocyte density and morphology was unchanged in the 
cortex of conditional mutants and there were no signs of microgliosis suggesting 
that mutant astrocytes do not undergo apoptosis. Surprisingly, albeit unchanged 
astrocyte density the number of Tdtomato expressing astrocytes was reduced in 
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mutant mice. Assessment of recombination efficiency of the ROSA26 and Fdft1 loci 
suggested that presence of the tdTomato allele reduced Fdft1 recombination. It is 
possible, that in turn also recombination of the ROSA26 locus was affected leading 
to reduced tdTomato expression. 
In mutant mice the expression of Hmgcr and Fdft1 was unchanged compared to 
controls while the expression of Apoe was slightly but significantly increased. 
Significantly reduced Fdft1 expression in astrocytes isolated from mutant mice 
without the tdTomato reporter indicated successful ablation of Fdft1 in the majority 
of cortical astrocytes. Remaining Fdft1 expression might be explained by differences 
in targeted cell subpopulations by Aldh1l1-CreERT2 and the ACSA2 antibody (see 
FACS data) used for magnetic cell isolation. These data suggest that cholesterol 
synthesis in the cortex is not globally impaired and it is possible that other cell types 
increased cholesterol synthesis and transport to compensate for the loss of 
astrocytic cholesterol synthesis as indicated in mice lacking cholesterol synthesis in 
myelinating glia or neurons (Saher et al., 2005; Fünfschilling et al., 2012). Future 
experiments are required to assess whether these expressional changes also 
translate to altered protein abundance.  
Immunohistochemical assessment indicated that mutant astrocytes survive but to 
ensure that these cells were viable, we analyzed them electrophysiologically. Mutant 
astrocytes exhibited electrophysiological properties indistinguishable from mature 
wild type cells, indicating that astrocytes are viable in conditional mutants and are 
not newly generated. Astrocytes are involved in maintaining BBB integrity via ApoE 
(Bell et al., 2012). We found that BBB integrity is preserved in conditional mutants 
preventing entry of Evans Blue from the blood circulation. Mutant animals also 
lacked edema formation as indicated by unchanged brain water content and normal 
Aqp4 protein levels. A slight increase of bodipy-cholesterol in the brains of mutant 
mice indicated that peripheral cholesterol might enter the brain at low levels. 
Investigation of the localization of this cholesterol derivate in the brain could promote 
the understanding whether peripheral cholesterol influences brain cholesterol 
metabolism in these mice. In summary, inactivation of cholesterol synthesis in adult 
astrocytes does not seem to affect astrocyte viability and survival as well as the 




3.3 Role of astrocytic cholesterol synthesis in cerebral β-amyloidosis 
 
The importance of cholesterol metabolism in Alzheimer’s disease is highlighted by 
the fact that 3 of the top 5 genetic risk factors for AD are involved in cholesterol 
metabolism (Bertram et al., 2007). Accumulating evidence from in vitro and 
preclinical studies indicate that cholesterol influences the generation and deposition 
of Aβ (Maulik et al., 2013). However, it is unclear how cholesterol synthesis by 
different cell types influences cerebral β-amyloidosis in vivo. To address this, we 
have inactivated SQS in astrocytes of 5xFAD mice (Oakley et al., 2006), an animal 
model of AD. Male astroSQS-5xFAD mice showed slightly reduced Aβ 
immunoreactivity (pan Aβ antibody) throughout the hippocampus compared to 
controls without reaching statistical significance. Similarly, soluble Aβ40 and Aβ42 
species as assessed by an electrochemiluminescence-linked immunoassay in the 
hippocampus appeared unaltered in astroSQS-5xFAD mice. In 5xFAD mice, Aβ 
deposition starts in the subiculum of the hippocampus at around two months of age 
and Aβ42 is found at higher levels than Aβ40 in the brains of 5xFAD mice (Oakley 
et al., 2006). Indeed, we found significantly reduced Aβ42 deposition in the 
subiculum of astroSQS-5xFAD mice. Future experiments will reveal whether this 
holds true during advanced disease in female animals and in aged animals. We next 
investigated possible explanations for the reduction of Aβ deposition in astroSQS-
5xFAD animals. 
Neuroinflammation with activation of astrocytes and microglia is a common feature 
in the brains of AD patients and mouse models of AD and both cell types are able 
to degrade Aβ (Solito and Sastre, 2012; Ferrer, 2017). ApoE was found to facilitate 
the degradation of Aβ by astrocytes and microglia in vitro (Koistinaho et al., 2004; 
Jiang et al., 2008). Furthermore, promoting lipidation of ApoE increased Aβ 
clearance by microglia in vitro and reduced Aβ deposition in vivo (Jiang et al., 2008). 
It is possible that loss of cholesterol synthesis in astrocytes could affect Aβ 
clearance by astrocytes and microglia. To address this, we investigated astrocyte 
and microglia responses in astroSQS-5xFAD mice. Immunohistochemical 
quantification and expression analysis did not reveal differences in the activation of 
astrocytes and microglia in astroSQS-5xFAD animals compared to 5xFAD controls. 
Also the expression of Aβ degrading enzymes was unaltered in the hippocampus of 
astroSQS-5xFAD mice compared to 5xFAD controls. So far, we have not addressed 
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regulation of these enzymes cell type specifically. Interestingly, the expression of 
Trem2 was significantly upregulated in the hippocampus of astroSQS-5xFAD 
animals compared to controls. Genetic variants of Trem2 have been identified that 
increase the risk of AD (reviewed in Ulrich et al., 2017). In mice, Trem2 is highly 
expressed in microglia cells (Hickman et al., 2013; Zhang et al., 2014) and Trem2 
has been shown to associate with various lipids (Wang et al., 2015) and binds ApoE 
(Atagi et al., 2015; Bailey et al., 2015; Yeh et al., 2016) and ApoJ in vitro (Yeh et al., 
2016). Furthermore, association of Aβ with lipoprotein particles enhanced uptake of 
Aβ by wild type microglia which was impaired in Trem2 deficient microglia (Yeh et 
al., 2016). In vivo, activation of Trem2 signaling was found in disease-associated 
microglia in 5xFAD mice (Keren-Shaul et al., 2017). Trem2 deficiency in 5xFAD 
mice resulted in reduction of plaque associated microglia (Wang et al., 2015; 2016) 
and increased Aβ deposition (Wang et al., 2015). Together, Trem2 seems to be 
involved in uptake of lipoprotein associated Aβ and reduced Trem2 expression could 
hinder Aβ clearance by microglia. It is therefore possible that increased expression 
of Trem2 by microglia could influence Aβ clearance in astroSQS-5xFAD mice. 
However, further studies are required to investigate this issue in more detail. 
In astroSQS mice, loss of astrocytic cholesterol synthesis did not lead to global 
changes in cholesterol homeostasis in the adult cortex and in the hippocampus. This 
could indicate that cholesterol demand in the brain is met by compensatory increase 
of cholesterol synthesis and transport by other cell types as reported in mice that 
lacked cholesterol synthesis in myelinating glia or forebrain projection neurons 
(Saher et al., 2005; Fünfschilling et al., 2012). Similarly, lipid transport could also be 
enhanced in astroSQS-5xFAD mice. Lipid transport within the brain likely influences 
the distribution and deposition of Aβ (Holtzman et al., 2012). Decreased ApoE 
lipidation (Hirsch-Reinshagen et al., 2004) resulted in increased Aβ deposition in 
mice lacking Abca1 (Koldamova et al., 2005; Wahrle et al., 2005) while 
overexpression of Abca1 resulted in decreased Aβ deposition (Wahrle et al., 2008). 
Therefore, in the next step we investigated cholesterol homeostasis in the 
hippocampus of 5xFAD and astroSQS-5xFAD animals by expressional analysis of 
the major genes involved in cholesterol synthesis, transport, uptake and excretion. 
Expression analyses revealed no differences in astroSQS-5xFAD animals 
compared to 5xFAD mice, suggesting that similar to wild type mice, tissue 
cholesterol homeostasis is not altered by loss of astrocytic cholesterol synthesis in 
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5xFAD animals. Surprisingly, ApoE protein levels were also unaltered in astroSQS 
and astroSQS-5xFAD compared to controls. Further study is required to assess 
whether microglia and neurons synthesize cholesterol when Fdft1 expression is 
inactivated in astrocytes, and which cell types generate ApoE. Whether lipid 
transport between cell types contributes to the reduction in Aβ deposition in 
astroSQS-5xFAD mice remains an open question. 
As discussed above, tissue cholesterol homeostasis seemed to be unaltered in 
astroSQS-5xFAD mutants. However, it remains unclear which cell types synthesize 
cholesterol in the absence of astrocytic cholesterol synthesis. Also, it is not well 
understood to which extent neurons require cholesterol supply by astrocytes in vivo. 
In vitro, cholesterol supported the clustering and endocytosis of APP and Bace1 
(Marquer et al., 2011), while reducing neuronal cholesterol content diminished Aβ 
generation (Simons et al., 1998; Wahrle et al., 2002). We therefore asked, whether 
loss of astrocytic cholesterol supply would in turn affect neuronal cholesterol content 
and thereby modulate APP processing to generate Aβ. To address this, APP C-
terminal fragments resulting from α-secretase cleavage (C83) and from 
amyloidogenic Bace1 processing (C99) were quantified in the hippocampus of 
astroSQS-5xFAD animals. However, we did not find a difference in the ratio of 
C83/C99 fragments in astroSQS-5xFAD and 5xFAD mice indicating that neuronal 
APP processing by α-secretase and Bace1 is not altered in astroSQS-5xFAD 
animals. It could be possible that neurons acquire cholesterol from other cells than 
astrocytes or synthesize enough cholesterol themselves. Further research is 
required to address these questions.  
Surprisingly, expression of the Bace1 homologue Bace2 was reduced in 5xFAD 
animals compared to astroSQS-5xFAD mice. In vitro, Bace2 cleaves APP at the β-
site (Hussain et al., 2000) but more prominently near the site of α-secretase 
cleavage (Yan et al., 2001). Overexpression of Bace2 reduced Aβ production in vitro 
and Bace2 could act as an Aβ degrading enzyme (Sun et al., 2006; Abdul-Hay et 
al., 2012). However, the role of Bace2 in vivo is far from understood and further 
research is required to assess whether Bace2 mediated APP processing could 




In summary, inactivation of cholesterol synthesis in astrocytes leads to a reduction 
in Aβ42 deposition in the subiculum of astroSQS-5xFAD mice. There, increased 
expression of Trem2 could potentially facilitate Aβ clearance by microglia cells. In 
mutant mice cholesterol homeostasis is largely unaltered, but it remains unclear 
which cell types compensate for the lack of astrocytic cholesterol synthesis. Loss of 
cholesterol support by astrocytes did not affect neuronal APP processing raising the 
question whether cell autonomous cholesterol synthesis is required in neurons to 
generate Aβ. 
 
3.4 Role of neuronal cholesterol synthesis in cerebral β-amyloidosis 
 
In neuroSQS animals, loss of cholesterol synthesis in forebrain projection neurons 
if fully compensated by increased synthesis and transport of cholesterol by other 
cell types, likely astrocytes (Fünfschilling et al., 2012). The extent of cell 
autonomous cholesterol synthesis by neurons however is incompletely understood. 
Furthermore, it is unclear whether external supply of cholesterol by other cells or 
neuronal cholesterol synthesis itself affects APP processing and Aβ generation. In 
astroSQS-5xFAD animals, neuronal APP processing was not altered leading to the 
question whether neuronal cholesterol synthesis influences APP processing and the 
deposition of Aβ. To address this question we inactivated cholesterol synthesis in 
neurons of 5xFAD mice. In these neuroSQS-5xFAD mutants Aβ42 deposition was 
unchanged compared to 5xFAD controls and quantification of APP C-terminal 
fragments in few animals did not suggest major changes in APP processing. 
However, these data have to be verified using increased animal numbers. In 
conclusion, the analysis of astroSQS-5xFAD and neuroSQS-5xFAD animals in 
parallel could provide valuable insight into the role of cellular cholesterol synthesis 
of different cell types and tissue cholesterol homeostasis in the generation and 








4.1 Solutions and buffers 
 
Avertin 
2 g 2,2,2 tribromoethanol 99% (T48402, Sigma) 
2 ml tert-Amyl alcohol (Sigma) 
96 ml H2O (40°C)  
Avertin was stirred for 30 min and was sterile filtered. The solution was stored at  
-20°C and heated to 37°C before usage. 
TBE buffer 20x (stock solution)  
1.8 M Trisbase  
1.8 M boric acid  
200 mM EDTA (ethylenediaminetetraacetic acid) 
Diluted 1:20 with ddH2O before use (1x TBE buffer). 
Sucrose buffer pH 7.4 (lysate preparation) 
(modified from Saab et al., 2016) 
320 mM sucrose 
10 mM Trisbase 
2 mM NaHCO3 
1 mM MgCl2 
cOmpleteTM protease inhibitors (Roche) 
PhosSTOPTM phosphatase inhibitors (Roche) 
TBS buffer pH 8 (lysate preparation) 
120 mM NaCl 
50mM Trisbase 
cOmpleteTM protease inhibitors (Roche) 
SDS buffer (lysate preparation) 
2% (w/v) sodium dodecyl sulfate (SDS) 




4x SDS buffer pH 6.8 
40% (v/v) glycerol  
240 mM Trisbase  
8% (v/v) SDS  
0.04% (w/v) bromophenol blue  
4X reducing sample buffer pH 7 
(modified from Schägger, 2006) 
150 mM Trisbase 
12% (w/v) SDS 
6% (v/v) dithiothreitol (500 mM) 
30% (w/v) glycerol 
0.05% Coomassie blue 
10x running buffer (Laemmli buffer) 
250 mM Trisbase 
1.92 M glycine  
1% (v/v) SDS 
diluted 1:10 with ddH2O before use 
1x MES buffer pH 7.3 
50 mM MES 
50 mM Trisbase 
0.1% (v/v) SDS 
1 mM EDTA 
10x transfer buffer 
480 mM Trisbase 
390 mM glycine 
10% (v/v) ethanol 
diluted 1:10 with ddH2O before use 
1x TBS-T pH 7.5 
50 mM Trisbase  
150 mM NaCl  




5% (w/v) non-fat dry milk powder in 1x TBST  
Tissue storage solution (FACS) 
2252 µl 1M glucose in 1x PBS 
2597 µl 1M NaHCO3 in 1x PBS 
Adjust pH to 7.3 with 1M NaOH. 
2000 ml DNAse (10 mg/ml) 
EDTA solution (FACS) 
50 mM EDTA 
100 mM L-cystein 
in ddH2O. 
Digest solution (FACS) 
2.5 ml tissue storage solution 
25 µl EDTA solution 
50 µl Papain (Worthington, LS003126) 
Inhibitor solution (FACS) 
50 ml 10% HEPES in 1x PBS 
450 ml MEM (Gibco) 
Adjust pH to 7.3 with 1M NaOH. 
11.261 ml 1M glucose in 1x PBS  
12.987 ml 1M NaHCO3 in 1x PBS 
500 mg bovine serum albumin 
FACS buffer 
2% bovine serum albumin (v/v) in 1xPBS 
10x PBS (histology) 
1.7 M NaCl  
0.04 M KCl  
0.04 M Na2HPO4  
0.018 M KH2PO4  
Adjusted to pH 7.2 with 1 M NaOH and diluted 1:10 with ddH2O (1x PBS) 
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16% (w/v) Paraformaldehye stock solution  
16% (w/v) paraformaldehyde cooked at 65°C for 15 min while stirring  
Add 5N NaOH until solution turns clear, filter and store at -20C°.  
0.2M Phosphate buffer (histology)  
0.36% (w/v) Sodiumdihydrogenphosphate (NaH2PO4)  
3.1% (w/v) di-Sodiumhydrogenphosphate (Na2HPO4)  
1% (w/v) NaCl  
4% (v/v) Paraformaldehye (PFA) for histology 
4% (v/v) paraformaldehyde  
0.1 M Phosphate buffer  
Anti-freeze solution 
300 ml glycerol 
300 ml ethylene glycol 
400 ml 1x PBS 
0.01 M sodium citrate buffer pH 6 
1.8 mM citric acid  
8.2 mM sodium citrate  
Prepared freshly before use.  
Tris buffer pH 7.6 (histology) 
50 mM Trisbase  
0.9% (w/v) NaCl  
Prepared freshly before usage.  
4.2 Antibodies 
 
Table 3: Primary antibodies 
Antibody Species Cat. No. Company Dilution Purpose 
APP poly-rabbit A8717 Sigma-Aldrich 1:2000 WB 
CAII poly-rabbit n.a. M. Said 
Ghandour 
1:100 IHC 
GAPDH mono-mouse CSA-335 Stressgen 1:2500 WB 
GFAP mono-mouse MAB3402 Chemicon 1:200 IHC 
GFP poly-goat 600-101-215 Rockland 1:500 IHC 
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Iba1 poly-rabbit 019-19741 Wako 1:1000 IHC 
Mac-3 mono-rat 553322 BD 
Pharmingen 
1:500 IHC 
NSE poly-rabbit AB951 Chemicon 1:500 IHC 
Olig2 poly-rabbit DF308 Charles Stiles, 
John Alberta 
1:100 IHC 
Parvalbumin poly-rabbit PV-28 Swant 1:1000 IHC 
RFP poly-rabbit 600-401-379 Rockland 1:500 / 
1:1500 
IHC / WB 
S100beta mono-rabbit ab52642 Abcam 1:200 IHC 





Aβ42 poly-rabbit 44-344 ThermoFisher 
Scientific 
1:500 IHC 
Aquaporin4 poly-rabbit sc-20812 
(H-80) 
Santa Cruz 1:500 IHC 
ApoE poly-goat AB947 Chemicon 1:2000 WB 
AN2 poly-rat n.a. J. Trotter 1:50 IHC 
 
Table 4: Secondary antibodies 
Antibody Species Cat. No. Company Dilution Purpose 





donkey 356 YO Proteins 1:500 IHC 
α-rabbit-Alexa488 donkey A-21206 Invitrogen 1:1000 / 
1:2000 
IHC 





donkey A-21202 Invitrogen 1:1000 / 
1:2000 
IHC 
α-mouse-HRP goat 115-035-003 Dianova 1:5000 WB 
α-goat-HRP rabbit A5420 Sigma 1:5000 WB 





Table 5: Genotyping primers 
Target locus Primer sequence In house 
Cat.no 
Aldh1l1-CreERT2 se: 5'-CAACTCAGTCACCCTGTGCTC-3' 20713 
 as: 5'-TTCTTGCGAACCTCATCACTCG-3' 08250 
Aldh1l1-Egfp se: 5'-CCCTTTCTAACCCTCTGGC-3' 22022 
 as: 5'-TCCTTGAAGAAGATGGTGCG 3' 15526 
CaMKIIα-Cre se: 5'-GGGAGGTAGGAAGAGCGATG-3' 06722 
 as: 5'-CCATGAGTGAACGAACCTGG-3' 06723 
Fdft1-flox se: 5'-ACGGGGCCAGGGTGCTTTTCTC-3' 02884 
 as 1: 5'-CTTCCCTTTCCTTGCCTTTCCATA-3' 32822 
 as 2: 5'-GGCTTATCTCTTCTCGCAATCTGA-3' 02720 
NG2-Eyfp se: 5'-CTAAGCGCGGGTCTGGCGCC -3' 33262 
 as 1: 5'-CGCTGAACTTGTGGCCGTTTA -3' 03312 
 as 2: 5'-ACAGCTTTCCTTCCAGAC -3' 05039 
Slc1a3-CreERT2 se: 5'-GAACTACAATCCTTTAAGGCTCACG -3' 26605 
 as 1: 5'-GCAGGACCTCGGGGTAGTCAC -3' 26606 
 as 2: 5'-CACCAGAGACGGAAATCCATCG -3' 26607 
ROSA26-
Tdtomato 
se: 5'-CTCTGCTGCCTCCTGGCTTCT -3' 14025 
 as 1: 5'-TCAATGGGCGGGGGTCGTT -3' 14024 
 as 2: 5'-CGAGGCGGATCACAAGCAATA -3' 14026 
ROSA26-Eyfp se: 5'-AAAGTCGCTCTGAGTTGTTAT -3' 03735 
 as 1: 5'-GCGAAGAGTTTGTCCTCAACC -3' 03736 
 as 2: 5'-GGAGCGGGAGAAATGGATATG -3' 03737 
5xFAD se: 5'-CCGCGCAGAACAGAAGGACAGAC -3' 19746 





Table 6: Quantitative RT-PCR primers 
Target locus Primer sequence In house 
Cat. no 
Abca1 se: 5‘-CTGTTTCCCCCAACTTCTG-3‘ 19854 
 as: 5’-TCTGCTCCATCTCTGCTTTC-3‘ 19855 
Apoe se: 5'-GACCCTGGAGGCTAAGGACT -3' 11856 
 as: 5'-AGAGCCTTCATCTTCGCAAT -3' 11857 
Apoj/ Clusterin se: 5'-GCCATGGATGTCCAGCTC -3' 36475 
 as: 5'-CACACAGTGCGGTCATCTTC -3' 36476 
Aqp4 se: 5'-TGGAGGATTGGGAGTCACC -3' 30574 
 as: 5'-TGAACACCAACTGGAAAGTGA -3' 30575 
App (human) se: 5'-CCGCTCTGCAGGCTGTTC -3'  
(McAlpine et al., 2009) 
37065 
 as: 5'-CGCGGACATACTTCTTTAGCATATT -3' 
(McAlpine et al., 2009) 
37066 
App (mouse) se: 5'-TCAGGATTTGAAGTCCGCCA -3' 
(Allué et al., 2016) 
37067 
 as: 5'-TTTGTTCGAACCCACATCTTCAG -3' 33760 
Bace1 se: 5'-CCCTTTCCTGCATCGCTAC -3' 12015 
 as: 5'-TACACACCCTTTCGGAGGTC -3' 12016 
Bace2 se: 5'-CCTGAGAGATGAGAATGCCAGT -3' 32361 
 as: 5'-ATCATGGGCTGAATGTAGAGC -3' 32362 
Cd9 se: 5'-GATATTCGCCATTGAGATAGCC -3' 13276 
 as: 5'-TGGTAGGTGTCCTTGTAAAACTCC -3' 13277 
Ch25h se: 5'-AAGACCTGGGCTGTTCCAG -3' 35387 
 as: 5'-GCCTCCCTTGTCCTTATGGT -3' 35388 
Cyp46a1 se: 5'-AACTTTGTCACCTTCTTCATTGC -3' 34294 
 as: 5'-CCATCACTGTGAATGCCAGA -3' 34295 
Ece1 se: 5'-GTGCTGGTGACGCTTCTG -3' 37230 
 as: 5'-ACATACCGGAGGCGTTCTT -3' 37231 
Ece2 se: 5'-GCTTTGAGACTGCACAGGAGA -3' 37232 
 as: 5'-CACCTCGGAGTGCAGGAC -3' 37233 
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Fdft1 se: 5'-CCAAACAGGACTGGGACAAG-3' 10843 
 as: 5'-GACGAGAAAGGCCAATTCC-3' 10844 
Gfap se: 5'-TCAAGAGGAACATCGTGGTAAAGA -3' 09414 
 as: 5'-TGCTCCTGCTTCGAGTCCTT -3' 09416 
Hmgcr se: 5'-TGATTGGAGTTGGCACCAT -3' 11766 
 as: 5'-TGGCCAACACTGACATGC -3' 11767 
Iba1 / Aif1 se: 5'-CCGAGGAGACGTTCAGCTAC -3' 09704 
 as: 5'-TGTTTTTCTCCTCATACATCAGAATC -3' 09705 
Ide se: 5'-TTCGATGTTTCCCATGAACA-3' 37063 
 as: 5'-AGGGGCACAGGAAAAACTG-3' 37064 
Lamp2 se: 5'-AAGGTGCAACCTTTTAATGTGAC -3' 32099 
 as: 5'-TGTCATCATCCAGCGAACAC -3' 32100 
Ldlr se: 5'-GATGGCTATACCTACCCCTCAA -3' 11887 
 as: 5'-TGCTCATGCCACATCGTC -3' 11888 
Lpl se: 5'-CTCGCTCTCAGATGCCCTAC -3' 35391 
 as: 5'-AGGCCTGGTTGTGTTGCTT -3' 35392 
Lrp1 se: 5'-ACCACCATCGTGGAAAATG -3' 34314 
 as: 5'-GTCCCAGCCACGGTGATA -3' 34315 
Lrp2 se: 5'-ATGCAGATGAGCACCACTGT -3' 35485 
 as: 5'-CACAGCCGTTTGTGATGAGA -3' 35486 
Rplp0 se: 5'-GATGCCCAGGGAAGACAG -3' 19908 
 as: 5'-ACAATGAAGCATTTTGGATAATCA -3' 19909 
Rps13 se: 5'-CGAAAGCACCTTGAGAGGAA -3' 19912 













All animal studies were performed at the Max Planck Institute of Experimental 
Medicine in compliance with the animal policies of the Max Planck Institute of 
Experimental Medicine and were approved by the German Federal State of Lower 
Saxony. All animals were housed in individually ventilated cages in groups of 3-5 
mice per cage and kept in a room with controlled temperature (~23°C) under 12 h 
light/dark cycle. Mice received either normal diet or the same diet supplemented 
with 0.5 % w/w cholesterol (ssniff Spezialdiäten GmbH). Food and water were 
provided ad libitum. Male and female C57Bl/6N mice generated at the Max Planck 
Institute of Experimental Medicine were used to maintain and expand mutant lines 
and served as controls during analyses where indicated. Assessment of 
recombination in the newly generated Aldh1l1-CreERT2 mouse line was performed 
using mice of both sexes at the age of 7-10 weeks unless otherwise stated. In all 
further studies male and female mice were analyzed separately at the ages 
indicated. 
 
5.1.1 Mouse mutants 
 
The ROSA26 flox-stop-flox-Tdtomato line (ROSA26-Tdtomato; Madisen et al., 
2010) and the ROSA26 flox-stop-flox-Eyfp line (ROSA26-Eyfp; Srinivas et al., 2001) 
were used as Cre reporters. Furthermore, we used BAC transgenic Aldh1l1-Egfp 
mice (Heintz, 2004), Slc1a3-CreERT2 mice (Mori et al., 2006), and NG2-Eyfp 
knock-in mice (Karram et al., 2008). As an Alzheimer’s disease model we used 
5xFAD mice (Oakley et al., 2006) that were back-crossed to C57Bl/6N wildtype 







5.1.2 Generation of Aldh1l1-CreERT2 mice 
 
Generation of Aldh1l1-CreERT2 mice was performed before the start of this project 
by Dr. Gesine Saher at the Max Planck Institute of Experimental Medicine as 
described elsewhere (Winchenbach et al., 2016). Briefly, a CreERT2 cassette 
(Sauer, 1994) under control of the Aldh1l1 promoter was inserted into exon 2 of the 
Aldh1l1 locus on a murine BAC (BAC RP23-7M9) by homologous recombination. 
After excision of the kanamycin resistance cassette the BAC insert was purified by 
size exclusion chromatography using a sepharose column and used for pronucleus 
injection. Three out of five founder mice bred to Cre reporter mice showed 
expression in brain. Based on the degree of expression in astrocytes and minimal 
expression in other cell types the Aldh1l1-CreERT2 line 02 was selected for further 
analyses. 
 
5.1.3 Generation of conditional Fdft1 mutants 
 
In order to conditionally inactivate cholesterol biosynthesis in astrocytes we crossed 
Aldh1l1-CreERT2 mice (Winchenbach et al., 2016) with SQS-flox mice (Saher et al., 
2005) to obtain Aldh1l1-CreERT2*Fdft1flox/flox mice (termed astroSQS mutants). In 
these mice the Fdft1 gene encoding squalene synthase, the enzyme catalyzing the 
first committed step in cholesterol synthesis, is flanked by loxP sites allowing 
excision of the gene by Cre recombinase. CreERT2-mediated recombination was 
induced in these animals by tamoxifen administration at desired time points (see 
below). Mutants lacking cell-autonomous cholesterol synthesis in forebrain 
projection neurons were generated by crossing the CaMKIIα-Cre line (Minichiello et 
al., 1999) to SQS-flox mice (termed neuroSQS mutants) as described previously 









5.1.4 Generation of 5xFAD mutants 
 
AstroSQS and neuroSQS mutants were crossed to 5xFAD mice (Oakley et al., 
2006) in order to generate astroSQS-5xFAD and neuroSQS-5xFAD mutants. All 
mouse breedings were designed to ensure hemizygosity of the offspring for the 
respective Cre alleles and for the 5xFAD transgene as well as homozygosity of the 
SQS-flox allele. An overview of the experimental groups (identical for male and 











Fdft1flox/flox or C57Bl/6N SQS-flox or wild type 




5.2 DNA purification and genotyping 
 
Genomic DNA from dissected cortices of adult mice was purified using the 
NucleoSpin® Tissue kit (Macherey-Nagel, 740952.250) and from tail or ear biopsies 
using the nexttecTM 1-step DNA Isolation Kit for Tissue and Cells (Nexttec 
Biotechnology) following the manufacturer’s instructions. Subsequently, DNA was 
either used undiluted or diluted 1:5 in ddH2O for genotyping by polymerase chain 
reaction (PCR, Thermocycler T3, Biometra) using GoTaq® polymerase and buffer 
(Promega, M784B and M791A) according to the protocols listed below. Finally, PCR 
products were supplemented with 5µl GelRedTM (1:4000 in ddH2O, Biotium, 41003) 
and loaded on 2% agarose gels. In order to estimate the size of amplified DNA 
fragments the GeneRuler 100 bp DNA Ladder (ThermoFisher Scientific, SM0241) 
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supplemented with GelRedTM was loaded as well. Gel electrophoresis was 
performed in a running chamber filled with 1x TBE buffer for 60 to 90 min at 120V. 
Pictures were taken under UV light using the Intas UV System (Intas Science 
Imaging Instruments GmbH). 
 
 
Aldh1l1-CreERT2  Aldh1l1-Egfp 
Master mix:  Master mix: 
1 µl DNA  1 µl DNA 
0.5 µl se-primer #20713 (10 pmol/µl)  0.75 µl se-primer #22022 (10 pmol/µl) 
0.5 µl as-primer #8250 (10 pmol/µl)  0.75 µl as-primer #15526 (10 pmol/µl) 
2 µl dNTP (2 mM)  2 µl dNTP (2 mM) 
4 µl GoTaq buffer (5x)  4 µl GoTaq buffer (5x) 
0.1 µl GoTaq  0.1 µl GoTaq 
11.9 µl ddH2O  11.4 µl ddH2O 
PCR program:  PCR program: 
1. 95°C 3 min  1. 94°C 5 min 
2. 56°C 30 s  2. 94°C 15 s 
3. 72°C 1 min  3. 51°C 30 s 
4. 95°C 30 s  4. 72°C 40 s 
➔ Step 2 to 4 for 36 cycles  ➔ Step 2 to 4 for 40 cycles 
5. 56°C 1 min  5. 72°C 5 min 
6. 72°C 10 min  6.   4°C pause 
7.   4°C pause    
 
CaMKIIα-Cre  Fdft1-flox 
 Master mix:  Master mix: 
1 µl DNA  1 µl DNA 
0.5 µl se-primer #06722 (10 pmol/µl)  0.5 µl se-primer #02884 (10 pmol/µl) 
0.5 µl as-primer #06723 (10 pmol/µl)  0.5 µl as-primer #32822 (10 pmol/µl) 
2 µl dNTP (2 mM)  0.5 µl as-primer2 #02720(10 pmol/µl) 
4 µl GoTaq buffer (5x)  2 µl dNTP (2 mM) 
0.1 µl GoTaq  4 µl GoTaq buffer (5x) 
78 
 
11.9 µl ddH2O  0.1 µl GoTaq 
PCR program:  11.4 µl ddH2O 
1. 94°C 2 min  PCR program: 
2. 58°C 30 s  1. 95°C 3 min 
3. 72°C 1 min 20 s  2. 58°C 30 s 
4. 94°C 30 s  3. 72°C 30 s 
➔ Step 2 to 4 for 30 cycles  4. 95°C 45 s 
5. 58°C 1 min  ➔ Step 2 to 4 for 36 cycles 
6. 72°C 2 min  5. 55°C 1 min 
7.   4°C pause  6. 72°C 5 min 
   7.   4°C pause 
 
NG2-Eyfp  Slc1a3-CreERT2 
 Master mix:  Master mix: 
1 µl DNA  1 µl DNA 
0.75 µl se-primer #33262 (10 pmol/µl)  1 µl se-primer #26605 (10 pmol/µl) 
0.2 µl as-primer #03312 (10 pmol/µl)  1 µl as-primer #26606 (10 pmol/µl) 
0.6 µl as-primer2 #05039 
(10pmol/µl) 
 0.5 µl as-primer2 #26607 (10 pmol/µl) 
2 µl dNTP (2 mM)  2 µl dNTP (2 mM) 
4 µl GoTaq buffer (5x)  4 µl GoTaq buffer (5x) 
0.1 µl GoTaq  0.1 µl GoTaq 
11.35 µl ddH2O  10.4 µl ddH2O 
PCR program:  PCR program: 
1. 95°C 3 min  1. 95°C 3 min 
2. 58°C 30 s  2. 58°C 30 s 
3. 72°C 1 min  3. 72°C 45 s 
4. 95°C 30 s  4. 95°C 30 s 
➔ Step 2 to 4 for 39 cycles  ➔ Step 2 to 4 for 35 cycles 
5. 58°C 40 s  5. 58°C 1 min 
6. 72°C 5 min  6. 72°C 10 min 




ROSA26-Tdtomato  ROSA26-Eyfp 
 Master mix:  Master mix: 
1 µl DNA  1 µl DNA 
0.5 µl se-primer #14025 (10 pmol/µl)  0.5 µl se-primer #03735 (10 pmol/µl) 
0.5 µl as-primer #14024 (10 pmol/µl)  0.5 µl as-primer #03736 (10 pmol/µl) 
0.5 µl as-primer2 #14026  
(10 pmol/µl) 
 0.5 µl as-primer2 #03737 (10 pmol/µl) 
2 µl dNTP (2 mM)  2 µl dNTP (2 mM) 
4 µl GoTaq buffer (5x)  4 µl GoTaq buffer (5x) 
0.1 µl GoTaq  0.1 µl GoTaq 
11.4 µl ddH2O  11.4 µl ddH2O 
PCR program:  PCR program: 
1. 95°C 3 min  1. 95°C 3 min 
2. 58°C 30 s  2. 56°C 30 s 
3. 72°C 1 min  3. 72°C 45 s 
4. 95°C 30 s  4. 95°C 30 s 
➔ Step 2 to 4 for 39 cycles  ➔ Step 2 to 4 for 39 cycles 
5. 58°C 40 s  5. 56°C 1 min 
6. 72°C 5 min  6. 72°C 10 min 
7.   4°C pause  7.   4°C pause 
 
5xFAD 
 Master mix: 
1 µl DNA 
0.5 µl se-primer #19746 (10 pmol/µl) 
0.5 µl as-primer #19747 (10 pmol/µl) 
2 µl dNTP (2 mM) 
4 µl GoTaq buffer (5x) 
0.1 µl GoTaq 




1. 95°C 3 min 
2. 66°C 25 s 
3. 72°C 40 s 
4. 95°C 25 s 
➔ Step 2 to 4 for 36 cycles 
5. 66°C 1 min 
6. 72°C 10 min 
7.   4°C pause 
 
 
5.3 Tamoxifen administration 
 
Tamoxifen (Sigma, T5648) was dissolved in corn oil (Sigma, C8267) at a 
concentration of 7.5 mg/ml and injected intraperitoneally at 75 µg/g body weight on 
5 consecutive days. In order to assess recombination in adult animals tamoxifen 
was administered to male and female mice at the age of 7-10 weeks unless stated 
otherwise. These mice were analyzed 12 (immunohistochemistry) and 20 days 
(electrophysiology) after the first tamoxifen injection. In astroSQS mutants, 
astroSQS-5xFAD mutants and corresponding controls tamoxifen was administered 
at P35 and animals were analyzed at P64 unless stated otherwise. 
 
5.4 Protein analyses 
 
5.4.1 Sample preparation 
 
Animals were sacrificed by cervical dislocation, peripheral organs (lung, liver, 
kidney, small intestine, heart) were extracted and snap frozen on dry ice. The 
thoracic spinal cord was extracted from the surrounding vertebrae and snap frozen 
on dry ice. The brain was quickly but carefully removed from the skull, the meninges 
were removed and the brain was immediately cooled down in 1x DPBS (Gibco, 
14190-094) on ice. Using a cooled brain matrix the brain was sliced in approx. 1 mm 
sagittal sections. While keeping the sections cooled and covered with 1x PBS, 
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regions of interest (cortex, hippocampus, cerebellum) were prepared and snap 
frozen on dry ice. Tissue samples were stored at -80°C until further processing. 
 
5.4.2 Tissue lysate preparation using sucrose buffer 
 
For protein and mRNA analyses tissue samples were homogenized in pre-cooled 
sucrose buffer containing protease and phosphatase inhibitors (cOmpleteTM, 
PhosSTOPTM, Roche) using the PT1200E homogenizer (Polytron) at max. speed 
for 20 seconds. For cortex samples 1000 µl, for hippocampus samples 300 µl and 
for peripheral organs 300-1000 µl of sucrose buffer were used for homogenization. 
For RNA purification 100 µl lysate were immediately transferred to 600 µl RLT buffer 
(Qiagen, 79216), vortexed and stored at -20°C until use. For Western blot analyses 
lysates were aliquoted and snap frozen on dry ice. Samples were stored at -80°C 
until use.  
 
5.4.3 Tissue lysate preparation using TBS and SDS buffers 
 
Hippocampal lysates of conditional 5xFAD mutants and controls were prepared by 
sequential protein extraction as described previously (Hüttenrauch et al., 2017) with 
slight modifications. Frozen tissue samples were weighed and homogenized in TBS 
buffer (6 µl/mg tissue) containing protease inhibitors (cOmpleteTM, Roche) using the 
PT1200E homogenizer (Polytron) at max. speed for 20 seconds. Lysates were then 
centrifuged at 17400 x g at 4°C for 20 min (OptimaTM TLX 120 Ultracentrifuge, 
Beckman Coulter), the supernatant containing TBS-soluble proteins was completely 
removed, aliquoted and frozen on dry ice. Subsequently, 200 µl of 2% SDS buffer 
(incl. protease inhibitors) were added to the pellet followed by sonication until 
complete resuspension of the pellet and centrifugation at 17400 x g at 4°C for 20 
min. The supernatant containing SDS-soluble proteins was aliquoted and frozen on 
dry ice. All samples were stored at -80°C until use. 
 
5.4.4 Measurement of protein concentration 
 
To determine total protein concentration of tissue lysates the DCTM Protein Assay 
kit (BIO-RAD, 5000112) was used which is based on the method described by Lowry 
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and colleagues (Lowry et al., 1951). Samples were analyzed in triplicates in Falcon® 
96-well flat bottom plates (Corning Incorporated, 353072) according to the 
manufacturer’s Microplate Assay Protocol. Absorbance was measured after 15 min 
of incubation at 736 nm using the Eon plate reader (Biotek). Protein concentrations 
were calculated by means of standard curves generated by serial dilutions of bovine 
serum albumin (BSA, BioLabs, B9000S) diluted in the respective buffers. 
 
5.4.5 Protein separation using SDS-PAGE 
 
Discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) initially described by Laemmli (Laemmli, 1970) was used to separate the 
proteins of a sample by size. SDS polyacrylamide gels of 1.5 mm thickness were 
casted using the Mini-PROTEANTM Handcast System (BIO-RAD). The separation 
gel solution (10% or 12% acrylamide) was overlayed with isopropyl alcohol and 
allowed to polymerize for 30 min. After rinsing with ddH2O the stacking gel solution 
was poured on the separation gel, a comb (10- or 15-well) was inserted and the gel 
was left to polymerize for 30 min. Tissue lysates homogenized in sucrose buffer 
were adjusted to equal protein concentration and mixed with 4x SDS buffer and 
dithiothreitol (DTT, final concentration 25 mM) and denatured at 70°C for 10 min. 
Samples were loaded at 10-25 µg/well as well as 5 µl of pre-stained protein ladder 
(PageRulerTM, ThermoFisher Scientific, 26619) and gels were run in 1x running 
buffer using the Mini-PROTEAN 3 chamber (BIO-RAD) connected to a power supply 
(BIO-RAD) at constant 200 V for 45-60 min depending on the size of the proteins of 
interest. 
  
5.4.6 Separation of APP C-terminal fragments 
 
In order to separate the small APP C-terminal fragments (~12-14 kDa) a different 
gel-buffer system was used. SDS-soluble protein fractions of hippocampal lysates 
were mixed with 4x reducing sample buffer (Schägger, 2006) using DTT instead of 
β-mercaptoethanol and adjusted to a final protein concentration of 2 µg/µl with 
ddH2O. Samples were then denatured at 70°C for 10 min and 20 µg/well sample 
(unless stated otherwise) as well as 5 µl of pre-stained protein ladder (PageRulerTM, 
ThermoFisher Scientific, 26619) were loaded onto NuPAGETM 12% Bis-Tris Protein 
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Gels (ThermoFisher Scientific, NP0341BOX). Gels were run in 1x MES buffer using 
the XCell SureLockTM Mini-Cell Electrophoresis System (ThermoFisher Scientific) 
connected to a power supply (BIO-RAD) at constant 200 V for 60 min. 
 
5.5 Western blotting 
 
5.5.1 Electrophoretic transfer 
 
Proteins were transferred to PVDF membranes (GE Healthcare, 10600023) using a 
tank blot system (XCell SureLockTM Mini-Cell Electrophoresis System, 
ThermoFisher Scientific). PVDF membranes were incubated for 1 min in methanol 
followed by rinsing two times with ddH2O. In order to provide sufficient buffer, 
blotting papers (GE Healthcare, 3030917) and blotting pads (ThermoFisher 
Scientific, EI9052) were pre-soaked in 1x transfer buffer. The blotting sandwich was 
placed on the cathode core of the blotting system (4x blotting paper → gel → 
membrane → 4x blotting paper → 6x blotting pad), the chamber was filled with 1x 
transfer buffer and blotting was performed at 38 V for 60 min at RT 
 
5.5.2 Immunodetection of proteins on PVDF membranes 
 
After blotting PVDF membranes were incubated in 1x TBS containing 0.05% Tween-
20 (Promega, H5151, 1x TBS-T) and 5% w/v skim milk powder (blocking buffer) for 
60 min under constant shaking at RT. Subsequently, membranes were transferred 
to 50 ml Falcon tubes containing 5 ml of primary antibodies diluted in blocking buffer 
and incubated under constant rotation overnight at 4°C. On the next day membranes 
were washed 3 times with 1x TBS-T for 10 min on a shaker at RT and then incubated 
in 50 ml Falcon tubes containing 5 ml of horseradish peroxidase (HRP)-coupled 
secondary antibodies diluted in blocking buffer for 1 h under constant rotation at RT. 
After washing 3 times with 1x TBS-T for 10 min membranes are incubated for 1 min 
in Enhanced Chemiluminescence solution (Western Lightning® Plus, Perkin Elmer) 





5.5.3 Densitometric quantification of immunoreactive bands 
 
Densitometric analysis of Western blot bands was performed on pictures taken with 
the ChemoCam Imager HR 16-3200 system using the gel analyzing function of the 
NIH ImageJ 1.50e software or using Image Studio 5.2 Lite (Li-Cor Biosciences). 
Results were normalized to loading controls (Actin or GAPDH) by calculating relative 
density values of the control protein and then dividing each density value of the 
protein band of interest by the corresponding relative density value of the control 
protein. Data were expressed as fold change to control animals and analyzed for 
statistical significance using GraphPad Prism 7 software. 
 
5.6 Electrochemiluminescence-linked immunoassay for Aβ 
 
For quantification of Aβ40 and Aβ42 peptides TBS- and SDS-soluble protein 
fractions of hippocampal lysates (see 5.4.3) were adjusted to equal protein 
concentrations (1.6 µg/µl for TBS samples and 3.6 µg/µl for SDS samples) using 
the respective buffers. Samples were then diluted in Assay Diluent 35 (TBS samples 
1:10, SDS samples 1:100) and analyzed in duplicates using the V-PLEX Aβ Peptide 
Panel 1 (6E10) Kit and the MESO QuickPlex SQ 120 instrument (Mesoscale 
Discovery). 
 
5.7 Fluorescence-activated cell sorting (FACS) 
 
Animals were sacrificed by cervical dislocation, meninges were removed, and 
cortices were prepared into small pieces on ice and subsequently transferred to pre-
cooled tissue storage solution. Tissue samples were centrifuged at 900 rpm 
(Heraeus Labofuge 400) for 1 min at 4°C, the supernatant was removed and the 
samples were incubated in pre-warmed, carbogenated digest solution in a water 
bath at 37°C under constant carbogen supply for 30min. Samples were 
subsequently centrifuged at 900 rpm for 1 min at 4°C and the supernatant was 
discarded. Papain digest was stopped by adding 15 ml inhibitor solution to the 
samples followed by centrifugation (900 rpm, 10min) and removal of the 
supernatant. Tissue pieces were homogenized three times by trituration in fresh 
tissue storage solution, followed by washing with inhibitor solution and centrifugation 
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at 900 rpm for 10min at 4°C. To separate astrocytes from myelin and other cells, 
tissue homogenates were underlayed sequentially with 20, 40 and 60% isotonic 
Percoll solution and centrifuged at 2300 rpm for 40min at 4°C. The interface 
containing astrocytes was removed, mixed with 10 ml FACS buffer and centrifuged 
for 10 min at 4°C. Cells were resuspended in 200 µl FACS buffer and stained with 
APC-labeled ACSA2 antibody (Miltenyi Biotec, 130-102-315) to identify astrocytes. 
Flow cytometry was performed using a FACS Aria flow cytometer (BD Biosciences). 
 
5.8 Magnetic cell isolation (MACS) 
 
Magnetic cell isolation of cortical astrocytes of astroSQS and control animals was 
performed as previously described (Berghoff et al., 2017a). Briefly, dissected 
cortices were processed according to the adult brain dissociation protocol (Miltenyi 
Biotec), followed by antibody labeling and magnetic isolation of astrocytes according 
to the Microbead kit protocol (Miltenyi Biotec, ACSA-2, 130–097-679). Isolated 
astrocytes were transferred to RLT buffer for RNA isolation (see below). 
 
5.9 RNA isolation, cDNA synthesis and quantitative RT-PCR 
 
5.9.1 RNA isolation from tissue samples 
 
RNA was isolated from tissue lysates that had previously been transferred to RLT 
buffer directly after homogenization using the RNeasy Mini Kit (Qiagen, 74106) 
according to the manufacturer’s instructions with slight modifications. Equal 
amounts of 70% ethanol were added to the sample, vortexed for 15 seconds and 
transferred to RNeasy columns. After centrifugation for 1 min at 13000 rpm 
(Heraeus Biofuge Pico) the flow through was discarded and 350 µl buffer RW1 were 
added to the columns. Samples were centrifuged at 13000 rpm for 1 min, the flow 
through discarded and DNAse digestion was performed for 15 min at RT. 
Subsequently, columns were again washed with 350 µl buffer RW1 and flow through 
as well as collection tubes were discarded after centrifugation at 13000 rpm for 
1min. Columns were placed in new collection tubes and washed two times with 500 
µl of buffer RPE by centrifugation at 13000 rpm for 1min after which flow through 
and collection tubes were discarded. Columns were placed in new collection tubes 
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and dried by centrifugation at 13000 rpm for 2 min. Finally, RNA was eluted two 
times with the same 30 µl of RNA grade H2O by centrifugation at 13000 rpm for 1 
min. Quality and concentration of RNA was measured using RNA Nano (Agilent) or 
a NanoDrop spectrophotometer. 
 
5.9.2 RNA isolation from MACS-purified samples 
 
MACS-purified cell lysates in RLT buffer were thawed rapidly in a water bath at 37°C 
followed by thorough vortexing. Cell lysates were processed using QIAshredder 
(Qiagen, 79654) and subsequently the RNeasy Micro Kit (Qiagen, 74004) including 
DNAse digest according to the manufacturer’s protocols. RNA was eluted by adding 
50 µl of RNA grade H2O to the columns, followed by 5 min incubation at RT and 
centrifugation for 1 min at 13000 rpm (Heraeus Biofuge Pico). A second volume of 
50 µl of fresh RNA grade H2O was added followed by centrifugation for 1 min at 
13000 rpm to elute residual RNA from the columns.  
 
5.9.3 RNA purification by precipitation 
 
RNA isolated from MACS-purified cells was purified by precipitation in order to 
maximize RNA concentration for cDNA synthesis. First, 1 µl of glycogen (20 µg/µl, 
Roche, 10901393001) were added to 100 µl of eluted RNA followed by vortexing. 
Subsequently, 50 µl 7.5 M ammonium acetate were added followed by vortexing 
and thorough mixing with 375 µl of 100% ethanol. Samples were left on ice for 30 
min and then centrifuged for 20 min at 13000 rpm (Heraeus Biofuge Pico). The 
supernatant was carefully removed and pellets were washed with 1 ml of 70% 
ethanol in RNA grade H2O by shaking and subsequent centrifugation for 5 min at 
13000 rpm. Afterwards, the supernatant was carefully removed and pellets were 
dried for approx. 5 min at RT to remove residual ethanol. Finally, 4 µl of RNA grade 







5.9.4 Complementary single stranded DNA (cDNA) synthesis 
 
Isolated RNA from cells or tissue samples was transcribed to cDNA using reverse 
transcriptase (SuperScriptTM III, ThermoFisher Scientific, 18080044) and a mixture 
of oligo-dT (0.06 µM, in house no. #09578) and random nonamer (12 µM, in house 
no. #04542) primers. RNA derived from tissue was used up to 1 µg for cDNA 
synthesis whereas the entire sample was used in case of MACS-isolated cells. 
Synthesis was performed according to the manufacturer’s instructions using the 
Thermocycler T3 (Biometra).  
 
5.9.5 Quantitative RT-PCR 
 
Quantitative RT-PCR was performed in triplicates on 384-well plates (Roche) using 
the GoTaq® qPCR Master Mix (Promega, A6002) and the LightCycler® 480 
Instrument (Roche). cDNA was diluted 1:5 in nuclease-free water (Promega) for 
MACS-isolated cells or used at 4 ng/well according to the following mix: 
 
2 µl cDNA 
0.4 µl se primer (10 pmol/µl) 
0.4 µl as primer (10 pmol/µl) 
5 µl GoTaq® Mix 
2.2 µl H2O 
 
Background subtraction and thresholding was performed using the LightCycler® 
480 software (Roche) and values were exported to MS Excel 2013. Expression of 
target genes was normalized to the housekeeping gene Rps13 (ribosomal protein 
S13) for MACS-isolated cells or to the mean of Rps13 and Rplp0 (60S acidic 










5.10.1 Perfusion and tissue fixation 
 
Mice were anesthetized by intraperitoneal injection of Avertin (0.2 ml/10 g body 
weight) and 500 µl of blood were collected by cardiac puncture directly followed by 
intracardial perfusion with PBS pre-warmed to 37°C for 10 min. Mutant mice 
expressing the Tdtomato reporter were subsequently perfused with 4% 
paraformaldehyde (PFA) for 20 min. Afterwards, peripheral organs (heart, kidney, 
liver, lung, small intestine) as well as brain and spinal cord were removed followed 
by immersion fixation overnight at 4°C. Tissues were stored in PBS containing 0.1% 
v/v PFA and 0.1% w/v sodium azide in the dark at 4°C until sectioning. For all other 
mice the brain was removed after perfusion with PBS, hemispheres were dissected, 
immersion fixed in 4% PFA for 48 h at 4°C followed by processing of one 
hemisphere for cryosectioning and the other for paraffin sectioning. 
 
5.10.2 Vibratome and cryostat sectioning 
 
Brains from mutant mice carrying the Tdtomato reporter were cut into 40 µm sagittal 
sections using either a Leica VT1000S or a Leica VT1200S vibratome (Leica 
Microsystems). For cryostat sectioning peripheral organs, spinal cord and 
hemispheres were cryoprotected in 15% and subsequently in 30% sucrose in PBS, 
frozen in embedding medium (Tissue-Tek®, 4583) on dry ice and stored at -80°C. 
Peripheral organs and spinal cord were cut on a cryostat (Leica) into 20 µm and 14 
µm thick sections, respectively. Frozen hemispheres of conditional 5xFAD mutants 
and controls were entirely cut into 40 µm serial sections collecting every 12th section 
in the same well of a Falcon® 12-well plate (Corning Incorporated, 353043) filled 
with anti-freeze solution. Sections were stored in anti-freeze solution at -20°C. 
 
5.10.3 Paraffin embedding and microtome sectioning 
 
Hemispheres of conditional 5xFAD mutants and controls were embedded in paraffin 




50% ethanol 1 h 
70% ethanol 2x 2 h 
96% ethanol 2x 2 h 
100% ethanol 2x 2 h 
Isopropyl alcohol 1 h 
Xylene 2x 2 h 
Paraffin 2x 2 h 
 
Subsequently, hemispheres were casted in blocks using 60°C warm paraffin, cooled 
to dry and stored at RT. Hemispheres were cut into 5 µm thick sagittal sections using 




5.10.4.1 Immunostaining of vibratome sections 
 
Free-floating sections were processed for immunohistochemistry by 
permeabilization in 0.4% Triton X-100 (Sigma, T8787-250ML) in PBS for 30 min 
followed by blocking in 4% horse serum (HS) and 0.2% Triton X-100 in PBS for 30 
min. Primary antibody incubation was carried out at 4°C overnight or for 48 h (CAII 
and Olig2) in 1% HS and 0.05% Triton X-100 in PBS. Incubation with secondary 
antibodies and DAPI (4',6-diamidino-2-phenylindole) was carried out at room 
temperature for 2 h in 1.5% HS in PBS. Sections were mounted in AquaPolymount 
(Polysciences). 
 
5.10.4.2 Immunostaining of frozen sections 
 
5.10.4.2.1 Staining of mounted sections 
 
Cryostat sections were collected on Superfrost® Plus slides (Thermo Scientific) and 
incubated in PBS for 5 min followed by blocking in 10% HS and 0.5% Triton X-100 
in PBS for 30 min. Sections were incubated with primary antibodies diluted in 10% 
HS and 0.3% Triton X-100 in PBS overnight at 4°C. Incubation with secondary 
90 
 
antibodies and DAPI was carried out at room temperature for 2 h in 10% HS and 
0.5% Triton X-100 in PBS and sections were mounted in AquaPolymount. 
 
5.10.4.2.2 Aβ staining of free-floating sections 
 
Sagittal sections (40 µm) were transferred to Costar® NetwellsTM (Corning 
Incorporated, 3478) and washed three times for 15 min with PBS to remove anti-
freeze solution. Sections were then incubated for 30 min in 0.3% H2O2 in 1x PBS, 
followed by washing three times in 1x PBS for 5 min each. Antigen retrieval for Aβ 
was performed by incubation in 88% formic acid for 10 min, directly followed by 
washing three times in 1x PBS for 5 min each. Sections were permeabilized in 0.1% 
Triton X-100 three times for 10 min followed by blocking in 4% goat serum in 1x 
PBS for 1h. Subsequently, sections were incubated with the pan Aβ antibody 
211218 (Synaptic Systems) diluted 1:500 in 1% goat serum overnight. The next day, 
sections were washed three times in 0.1% Triton X-100 in 1x PBS for 10 min each, 
followed by two washing steps in 1x PBS. Immunodetection was performed using 
the LSAB2 kit (Dako), followed by incubation with the HRP substrate 3,3’-
Diaminobenzidine (DAB) using the DAB Substrate Kit (Zytomed Systems GmbH, 
DAB530) for 30s. After washing in 1x PBS three times for 10 min, sections were 
mounted on Superfrost® Plus slides (Thermo Scientific) and dried overnight at 
37°C. The next day, sections were counterstained with haematoxylin and 
dehydrated by decreasing ethanol dilutions (50%, 70%, 90%, and 100% for 5 min 
each) followed by xylene/isopropyl alcohol (1:1, 5 min) and two times xylene (10 
min) before mounting (Eukitt). 
 
5.10.4.3 Immunostaining of paraffin sections 
 
Paraffin sections were incubated at 60°C for 10 min and deparaffinized two times in 
xylene and in xylene/isopropyl alcohol (1:1) for 10 min each. Sections were then re-
hydrated in increasing ethanol dilutions (100%, 90%, 70%, 50%) for 5 min each and 
finally incubated in ddH2O for 5 min. Antigen retrieval was performed by boiling 
sections in sodium citrate buffer (0.01 M, pH 6.0) for 10 min in a microwave and for 
immunofluorescence additionally by incubation in 0.1% Triton X-100 in PBS for 15 
min. For Aβ staining sections were additionally incubated in 88% formic acid for 3 
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min at RT. For chromogenic immunostaining sections were then incubated in tris-
buffered saline (Tris buffer) containing 2% w/v skim milk powder for 5 min and 
transferred to Shandon Coverplates (ThermoFisher Scientific) followed by washing 
with Tris buffer containing 2% milk. For immunofluorescence sections were 
incubated in 10% v/v FCS (fetal calf serum) and 4% w/v skim milk powder in PBS 
for 1 h at RT followed by incubation with primary antibodies in 10% FCS in PBS 
overnight in a humid chamber at 4°C. Chromogenic immunostaining was continued 
by applying 3% hydrogen peroxide for 5 min followed by  washing with Tris buffer 
containing 2% milk and incubation in Protein Bock Serum-Free (Dako) for 10 min. 
Sections were then incubated with primary antibodies in Antibody Diluent (Dako) at 
4°C overnight. Immunofluorescence was completed on the next by washing three 
times in 0.1% Triton X-100 in PBS for 5 min and for another 5 min in PBS followed 
by incubation with fluorescently labelled secondary antibodies and DAPI in 10% 
FCS in PBS for 1 h at RT. Finally, sections were washed three times with PBS for 5 
min and mounted using AquaPolymount. For chromogenic immunostaining sections 
were washed in Tris buffer containing 2% milk followed by immunodetection using 
the LSAB2 kit (Dako). First, sections were incubated with biotinylated secondary 
antibodies for 10 min, washed in Tris buffer containing 2% milk and then incubated 
with streptavidin-coupled HRP for 10 min. Sections were then washed in Tris buffer 
without milk for 5 min followed by incubation with the HRP substrate 3,3’-
Diaminobenzidine (DAB) using the DAB Substrate Kit (Zytomed Systems GmbH, 
DAB530) for 5 to 15 min depending on staining intensity. Subsequently, sections 
were washed two times in ddH2O, nuclei were stained with haematoxylin and 
sections were dehydrated by decreasing ethanol dilutions (50%, 70%, 90%, and 
100% for 5 min each) followed by xylene/isopropyl alcohol (1:1, 5 min) and two times 
xylene (10 min) before mounting (Eukitt). 
 
5.11 Measurement of serum cholesterol 
 
Blood collected during perfusion was allowed to clot for 1 h at RT and serum was 
prepared by centrifugation for 10 min at 5000 rpm (Heraeus Biofuge Pico). 
Cholesterol measurements were performed using the architectII system (Abbott 
Diagnostics) by technicians of the Central Laboratory for Clinical Chemistry at the 
University Medical Center, Göttingen. 
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5.12 EdU proliferation assay 
 
To label proliferating cells in adult animals, EdU (50µg/g) dissolved in saline was 
injected intraperitoneally on 16 consecutive days. Staining of 50 µm sagittal 
vibratome sections was performed using the Click-iT Plus EdU Alexa Fluor 647 
Imaging Kit (ThermoFisher Scientific, C10640) following the manufacturer’s 
instructions. Sections were additionally labeled using an NG2 (AN2, J. Trotter) and 




Acute forebrain slices from 8 weeks old wild type and astroSQS-Tdto (each n=3) 
mice were prepared as described previously (Schnell et al., 2015). Briefly, after deep 
isoflurane narcosis, animals were decapitated, the forebrain was prepared and 
placed in ice-cooled, carbogen-saturated (95 % O2, 5 % CO2) artificial cerebrospinal 
fluid (aCSF; in mM: 118 NaCl, 3 KCl, 1.5 CaCl2, 1 MgCl2, 1 NaH2PO4, 25 NaHCO3, 
and 30 D-glucose; 330 mosmol/l, pH7.4). Sagittal sections (300 μm) were cut on a 
vibroslicer (VT1200 S, Leica) and stored in aCSF at 35–36°C for at least 30 min. 
Sulforhodamine 101 (SR101, 1 µM) staining was performed for 20 min at 34°C 
followed by washing in aCSF for 10 min at 34 °C as described previously (Kafitz et 
al., 2008; Schnell et al., 2012). Subsequently, slices were transferred to the 
recording chamber and kept submerged by a platinum grid with nylon fibers for 
mechanical stabilization. The chamber was mounted on an upright microscope 
(Axioscope FS, Zeiss Germany, 40x objective) and continuously perfused with 
aCSF at room temperature at a flow rate of 5–10 ml/min. Astrocytes were identified 
by SR101 staining in epifluorescence illumination (white-LED, Lumencor Sola SE 
II). For documentation, images of recorded tdTomato-expressing cells were taken 
with a CCD camera (Sensicam, PCO) and Imaging workbench 6.0 software (Indec 
Biosystems). Whole-cell voltage-clamp recordings were obtained with a MultiClamp 
700B Amplifier (Molecular Devices). Patch electrodes were pulled from borosilicate 
glass capillaries (Biomedical Instruments, Zülpich, Germany) using a horizontal 
pipette-puller (Zeitz-Instrumente, Germany). Electrodes were filled with (in mM) 125 
KCl, 1 CaCl2, 2 MgCl2, 4 Na2ATP, 10 EGTA, 10 HEPES (pH adjusted to 7.2 with 
KOH) leading to tip resistance of 2 – 6 MΩ. Currents were low-pass filtered at 3 kHz, 
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and sampled at 10 kHz and recorded with pClamp 10 software (Molecular Devices) 
and stored for off-line analysis. Membrane potentials (Vm) were recorded at steady 
state and astrocytes were voltage-clamped to –80 mV and characterized by a 
voltage step protocol. Therefore, cells were hyperpolarized by -80 to -10 mV and 
depolarized by +10 mV to +110 mV voltage steps (10 mV increment). Mean I-V 
curves were calculated and inward and outward currents were compared at maximal 
hyperpolarization (∆I = I-80 - I-160) and maximal depolarization (∆I = I30 – I-80). The 
membrane resistance (Ri) was calculated from the change of the holding current in 
response to the first hyperpolarizing voltage step to -90 mV. Statistical analysis was 
performed using 1way ANOVA. 
 
5.14 Assessment of blood-brain barrier permeability 
 
Injection of Evans Blue and sodium fluorescein as well as quantification of tracer 
extravasation was performed as previously described (Berghoff et al., 2017a). 
Injection of bodipy-cholesterol (Avanti Polar Lipids) and the measurement of 
extravasated bodipy-cholesterol was performed as described (Berghoff et al., 
2017b). 
 
5.15 Microscopy and quantification of immunoreactivity 
 
Specimens were analyzed by epifluorescence microscopy using a Plan-Apochromat 
20x/0.8 objective (Zeiss Axio Oberser.Z1 with ApoTome.2) and the ZEN 2 software 
(Zeiss). Confocal laser scanning microscopy was performed using a Leica SP2 
equipped with a HC PL APO lambda blue 20x/0.7 objective or with a Leica SP5 
(HCX PL APO CS 20x/0.7, HCX PL APO lambda blue 40x/1.25, HCX PL APO CS 
100x/1.44 objectives) using the Leica Confocal Software (Leica Microsystems). 
Immunolabeling visualized by DAB was analyzed using an Axio Imager.Z1 (Zeiss) 
equipped with an AxioCam MRc3, 0.63x Camera Adaptor and the ZEN 2012 blue 
edition software using a 20x objective (Plan-Apochromat 20x/0.8). Images were 
processed with NIH ImageJ and quantification of areas (GFAP, pan Aβ, Aβ42) was 
performed by applying a semi-automated ImageJ software macro for thresholding 
and color deconvolution. Fluorescent images of AQP4 and Iba1 immunolabeling 
were thresholded manually using NIH ImageJ. Quantification of Aβ 
94 
 
immunoreactivity using the pan Aβ antibody (211218, Synpatic Systems) was 
performed on every 12th section (see 5.11.4.2.2) of serial sections throughout the 
hippocampus of one hemisphere. Quantification of Aβ42 deposition in the subiculum 
was performed on paraffin sections of the lateral hippocampus. Analysis was 
performed on sections that corresponded to at least 60 µm distance in the 
hippocampus to avoid overlapping quantification. Analysis of Aβ42 deposition was 
performed by a different investigator blind to the experimental groups. 
 
5.16 Statistical analysis 
 
Statistical analysis was performed by unpaired Student’s t-test for comparison of 
two groups while one-way ANOVA with Tukey’s multiple comparison test was used 
for comparison of more than two groups using the GraphPad Prism 7 software. P 
values in the figure legends are shown with *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001, or with #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 for significant 
differences relative to wild type controls. Outliers were identified using the Grubb’s 
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